CA2894005A1 - Compositions therapeutiques renfermant des composes skq et leurs utilisations en vue de traiter et prevenir les maladies et troubles mitochondriaux - Google Patents

Info

Publication number

CA2894005A1

CA2894005A1 CA2894005A CA2894005A CA2894005A1 CA 2894005 A1 CA2894005 A1 CA 2894005A1 CA 2894005 A CA2894005 A CA 2894005A CA 2894005 A CA2894005 A CA 2894005A CA 2894005 A1 CA2894005 A1 CA 2894005A1

Authority

CA

Canada

Prior art keywords

deficiency

syndrome

mitochondrial

substituted

unsubstituted

Prior art date

2015-06-08

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Abandoned

Links

• Espacenet
• Global Dossier
• CIPO
• Discuss

• 239000000203 mixture Substances 0.000 title claims abstract description 46
• 208000012268 mitochondrial disease Diseases 0.000 title claims description 93
• 150000001875 compounds Chemical class 0.000 title abstract description 117
• 230000001225 therapeutic effect Effects 0.000 title description 12
• 238000000034 method Methods 0.000 claims abstract description 97
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 85
• 201000010099 disease Diseases 0.000 claims abstract description 53
• 150000003839 salts Chemical class 0.000 claims abstract description 49
• 239000011203 carbon fibre reinforced carbon Substances 0.000 claims description 207
• 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 173
• 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 136
• -1 cofactors Substances 0.000 claims description 114
• 229910052739 hydrogen Inorganic materials 0.000 claims description 103
• 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 95
• 230000007812 deficiency Effects 0.000 claims description 93
• 201000009623 Myopathy Diseases 0.000 claims description 72
• 208000021642 Muscular disease Diseases 0.000 claims description 71
• CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 claims description 68
• 229910052794 bromium Inorganic materials 0.000 claims description 66
• 229910052801 chlorine Inorganic materials 0.000 claims description 66
• 229910052731 fluorine Inorganic materials 0.000 claims description 66
• 230000002438 mitochondrial effect Effects 0.000 claims description 61
• 208000011580 syndromic disease Diseases 0.000 claims description 59
• 230000002829 reductive effect Effects 0.000 claims description 52
• 206010003591 Ataxia Diseases 0.000 claims description 51
• 108020005196 Mitochondrial DNA Proteins 0.000 claims description 48
• 208000001992 Autosomal Dominant Optic Atrophy Diseases 0.000 claims description 43
• 239000012453 solvate Substances 0.000 claims description 43
• 208000014644 Brain disease Diseases 0.000 claims description 38
• 208000032274 Encephalopathy Diseases 0.000 claims description 38
• 239000003814 drug Substances 0.000 claims description 35
• 229940124597 therapeutic agent Drugs 0.000 claims description 32
• 206010008025 Cerebellar ataxia Diseases 0.000 claims description 30
• 229910052799 carbon Inorganic materials 0.000 claims description 30
• 208000024891 symptom Diseases 0.000 claims description 30
• 239000000090 biomarker Substances 0.000 claims description 28
• 230000002159 abnormal effect Effects 0.000 claims description 27
• 206010012601 diabetes mellitus Diseases 0.000 claims description 27
• ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims description 25
• 206010028629 Myoglobinuria Diseases 0.000 claims description 24
• 235000017471 coenzyme Q10 Nutrition 0.000 claims description 24
• 229940088594 vitamin Drugs 0.000 claims description 24
• 229930003231 vitamin Natural products 0.000 claims description 24
• 235000013343 vitamin Nutrition 0.000 claims description 24
• 239000011782 vitamin Substances 0.000 claims description 24
• 208000001749 optic atrophy Diseases 0.000 claims description 23
• 230000000750 progressive effect Effects 0.000 claims description 23
• 201000000915 Chronic Progressive External Ophthalmoplegia Diseases 0.000 claims description 22
• 206010010904 Convulsion Diseases 0.000 claims description 22
• 208000032087 Hereditary Leber Optic Atrophy Diseases 0.000 claims description 22
• 201000000639 Leber hereditary optic neuropathy Diseases 0.000 claims description 22
• 208000009415 Spinocerebellar Ataxias Diseases 0.000 claims description 22
• 239000003242 anti bacterial agent Substances 0.000 claims description 22
• 230000000567 anti-anemic effect Effects 0.000 claims description 22
• 230000002785 anti-thrombosis Effects 0.000 claims description 22
• 229940124344 antianaemic agent Drugs 0.000 claims description 22
• 239000003173 antianemic agent Substances 0.000 claims description 22
• 229940088710 antibiotic agent Drugs 0.000 claims description 22
• 239000003146 anticoagulant agent Substances 0.000 claims description 22
• 229940034982 antineoplastic agent Drugs 0.000 claims description 22
• 239000002246 antineoplastic agent Substances 0.000 claims description 22
• 229960004676 antithrombotic agent Drugs 0.000 claims description 22
• 239000002327 cardiovascular agent Substances 0.000 claims description 22
• 229940125692 cardiovascular agent Drugs 0.000 claims description 22
• 229940124448 dermatologic drug Drugs 0.000 claims description 22
• 229940088597 hormone Drugs 0.000 claims description 22
• 239000005556 hormone Substances 0.000 claims description 22
• 239000002955 immunomodulating agent Substances 0.000 claims description 22
• 229940121354 immunomodulator Drugs 0.000 claims description 22
• 150000003431 steroids Chemical class 0.000 claims description 22
• IMCGHZIGRANKHV-AJNGGQMLSA-N tert-butyl (3s,5s)-2-oxo-5-[(2s,4s)-5-oxo-4-propan-2-yloxolan-2-yl]-3-propan-2-ylpyrrolidine-1-carboxylate Chemical compound O1C(=O)[C@H](C(C)C)C[C@H]1[C@H]1N(C(=O)OC(C)(C)C)C(=O)[C@H](C(C)C)C1 IMCGHZIGRANKHV-AJNGGQMLSA-N 0.000 claims description 22
• 208000002155 Cytochrome-c Oxidase Deficiency Diseases 0.000 claims description 21
• 206010036802 Progressive external ophthalmoplegia Diseases 0.000 claims description 20
• 208000016354 hearing loss disease Diseases 0.000 claims description 20
• 230000006870 function Effects 0.000 claims description 19
• 210000003470 mitochondria Anatomy 0.000 claims description 19
• 206010011878 Deafness Diseases 0.000 claims description 17
• 201000010802 Wolfram syndrome Diseases 0.000 claims description 17
• 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 claims description 17
• 230000001965 increasing effect Effects 0.000 claims description 17
• 201000011561 mitochondrial DNA depletion syndrome 7 Diseases 0.000 claims description 17
• 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 claims description 17
• 102000018832 Cytochromes Human genes 0.000 claims description 16
• 108010052832 Cytochromes Proteins 0.000 claims description 16
• 231100000895 deafness Toxicity 0.000 claims description 16
• 230000004064 dysfunction Effects 0.000 claims description 16
• 210000003205 muscle Anatomy 0.000 claims description 16
• 102000000634 Cytochrome c oxidase subunit IV Human genes 0.000 claims description 15
• 108090000365 Cytochrome-c oxidases Proteins 0.000 claims description 15
• JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 15
• LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 claims description 15
• 208000015181 infectious disease Diseases 0.000 claims description 15
• 229940076788 pyruvate Drugs 0.000 claims description 15
• 229910052717 sulfur Inorganic materials 0.000 claims description 15
• 206010011891 Deafness neurosensory Diseases 0.000 claims description 14
• 208000009966 Sensorineural Hearing Loss Diseases 0.000 claims description 14
• 208000023573 sensorineural hearing loss disease Diseases 0.000 claims description 14
• 102000007368 Ataxin-7 Human genes 0.000 claims description 13
• 108010032953 Ataxin-7 Proteins 0.000 claims description 13
• 102100029348 CDGSH iron-sulfur domain-containing protein 2 Human genes 0.000 claims description 13
• 208000031229 Cardiomyopathies Diseases 0.000 claims description 13
• 201000007021 Wolfram syndrome 1 Diseases 0.000 claims description 13
• 208000010194 infantile onset spinocerebellar ataxia Diseases 0.000 claims description 13
• 208000006443 lactic acidosis Diseases 0.000 claims description 13
• 208000033808 peripheral neuropathy Diseases 0.000 claims description 13
• 102100034215 AFG3-like protein 2 Human genes 0.000 claims description 12
• 208000002177 Cataract Diseases 0.000 claims description 12
• 208000010354 Coenzyme Q10 deficiency Diseases 0.000 claims description 12
• 206010012289 Dementia Diseases 0.000 claims description 12
• 108010024636 Glutathione Proteins 0.000 claims description 12
• 108010053070 Glutathione Disulfide Proteins 0.000 claims description 12
• 101000989662 Homo sapiens CDGSH iron-sulfur domain-containing protein 2 Proteins 0.000 claims description 12
• 208000006136 Leigh Disease Diseases 0.000 claims description 12
• 208000017507 Leigh syndrome Diseases 0.000 claims description 12
• 206010058799 Mitochondrial encephalomyopathy Diseases 0.000 claims description 12
• XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 claims description 12
• 208000027462 combined oxidative phosphorylation deficiency 16 Diseases 0.000 claims description 12
• 208000027429 combined oxidative phosphorylation deficiency 9 Diseases 0.000 claims description 12
• 235000018417 cysteine Nutrition 0.000 claims description 12
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 12
• 230000002354 daily effect Effects 0.000 claims description 12
• 206010015037 epilepsy Diseases 0.000 claims description 12
• 230000014509 gene expression Effects 0.000 claims description 12
• RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 12
• YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 claims description 12
• 230000008774 maternal effect Effects 0.000 claims description 12
• YPZRWBKMTBYPTK-UHFFFAOYSA-N oxidized gamma-L-glutamyl-L-cysteinylglycine Natural products OC(=O)C(N)CCC(=O)NC(C(=O)NCC(O)=O)CSSCC(C(=O)NCC(O)=O)NC(=O)CCC(N)C(O)=O YPZRWBKMTBYPTK-UHFFFAOYSA-N 0.000 claims description 12
• 208000024412 Friedreich ataxia Diseases 0.000 claims description 11
• 206010021118 Hypotonia Diseases 0.000 claims description 11
• 208000007379 Muscle Hypotonia Diseases 0.000 claims description 11
• 208000027089 Parkinsonian disease Diseases 0.000 claims description 11
• 206010034010 Parkinsonism Diseases 0.000 claims description 11
• 201000003400 infantile cerebellar-retinal degeneration Diseases 0.000 claims description 11
• 208000002780 macular degeneration Diseases 0.000 claims description 11
• 125000001453 quaternary ammonium group Chemical group 0.000 claims description 11
• 208000006446 thiamine-responsive megaloblastic anemia syndrome Diseases 0.000 claims description 11
• 102000006589 Alpha-ketoglutarate dehydrogenase Human genes 0.000 claims description 10
• 108020004306 Alpha-ketoglutarate dehydrogenase Proteins 0.000 claims description 10
• 201000005943 Barth syndrome Diseases 0.000 claims description 10
• 206010019663 Hepatic failure Diseases 0.000 claims description 10
• 101000780591 Homo sapiens AFG3-like protein 2 Proteins 0.000 claims description 10
• 208000009437 Wolfram syndrome 2 Diseases 0.000 claims description 10
• 230000001154 acute effect Effects 0.000 claims description 10
• 206010064930 age-related macular degeneration Diseases 0.000 claims description 10
• 208000007502 anemia Diseases 0.000 claims description 10
• 208000026797 combined oxidative phosphorylation deficiency 18 Diseases 0.000 claims description 10
• 230000001667 episodic effect Effects 0.000 claims description 10
• 208000036546 leukodystrophy Diseases 0.000 claims description 10
• 208000007903 liver failure Diseases 0.000 claims description 10
• 231100000835 liver failure Toxicity 0.000 claims description 10
• 201000003656 mitochondrial complex III deficiency nuclear type 2 Diseases 0.000 claims description 10
• 230000007823 neuropathy Effects 0.000 claims description 10
• 230000000241 respiratory effect Effects 0.000 claims description 10
• 231100000879 sensorineural hearing loss Toxicity 0.000 claims description 10
• 201000003670 spastic ataxia 3 Diseases 0.000 claims description 10
• 108010018424 Carnitine O-palmitoyltransferase Proteins 0.000 claims description 9
• 102000028526 Dihydrolipoamide Dehydrogenase Human genes 0.000 claims description 9
• 108010028127 Dihydrolipoamide Dehydrogenase Proteins 0.000 claims description 9
• 208000014094 Dystonic disease Diseases 0.000 claims description 9
• 206010016228 Fasciitis Diseases 0.000 claims description 9
• 208000001984 Multiple Symmetrical Lipomatosis Diseases 0.000 claims description 9
• 201000002481 Myositis Diseases 0.000 claims description 9
• 102000030766 Thiamin Pyrophosphokinase Human genes 0.000 claims description 9
• 108010001088 Thiamin pyrophosphokinase Proteins 0.000 claims description 9
• JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 claims description 9
• 208000010118 dystonia Diseases 0.000 claims description 9
• 230000012010 growth Effects 0.000 claims description 9
• 230000004060 metabolic process Effects 0.000 claims description 9
• 201000011171 multiple symmetric lipomatosis Diseases 0.000 claims description 9
• 201000001119 neuropathy Diseases 0.000 claims description 9
• BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 claims description 9
• 125000005496 phosphonium group Chemical group 0.000 claims description 9
• 239000011721 thiamine Substances 0.000 claims description 9
• KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 claims description 9
• 235000019157 thiamine Nutrition 0.000 claims description 9
• 229960003495 thiamine Drugs 0.000 claims description 9
• HCAJQHYUCKICQH-VPENINKCSA-N 8-Oxo-7,8-dihydro-2'-deoxyguanosine Chemical compound C1=2NC(N)=NC(=O)C=2NC(=O)N1[C@H]1C[C@H](O)[C@@H](CO)O1 HCAJQHYUCKICQH-VPENINKCSA-N 0.000 claims description 8
• 208000011403 Alexander disease Diseases 0.000 claims description 8
• CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 8
• 208000016285 Movement disease Diseases 0.000 claims description 8
• DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 claims description 8
• WDJHALXBUFZDSR-UHFFFAOYSA-M acetoacetate Chemical compound CC(=O)CC([O-])=O WDJHALXBUFZDSR-UHFFFAOYSA-M 0.000 claims description 8
• 208000027432 combined oxidative phosphorylation deficiency 14 Diseases 0.000 claims description 8
• 208000026615 cytochrome-c oxidase deficiency disease Diseases 0.000 claims description 8
• 201000011540 mitochondrial DNA depletion syndrome 4a Diseases 0.000 claims description 8
• 210000000056 organ Anatomy 0.000 claims description 8
• 208000023434 Alpers-Huttenlocher syndrome Diseases 0.000 claims description 7
• 102000014461 Ataxins Human genes 0.000 claims description 7
• 108010078286 Ataxins Proteins 0.000 claims description 7
• 206010012559 Developmental delay Diseases 0.000 claims description 7
• 108010024882 Electron Transport Complex III Proteins 0.000 claims description 7
• 102000015782 Electron Transport Complex III Human genes 0.000 claims description 7
• 208000034800 Leukoencephalopathies Diseases 0.000 claims description 7
• 201000002169 Mitochondrial myopathy Diseases 0.000 claims description 7
• 208000007101 Muscle Cramp Diseases 0.000 claims description 7
• 208000002033 Myoclonus Diseases 0.000 claims description 7
• 208000013234 Pearson syndrome Diseases 0.000 claims description 7
• 208000034972 Sudden Infant Death Diseases 0.000 claims description 7
• 206010042440 Sudden infant death syndrome Diseases 0.000 claims description 7
• 206010044565 Tremor Diseases 0.000 claims description 7
• 206010071434 biotinidase deficiency Diseases 0.000 claims description 7
• 208000019423 liver disease Diseases 0.000 claims description 7
• 201000011593 mitochondrial complex III deficiency nuclear type 1 Diseases 0.000 claims description 7
• 108010007425 oligomycin sensitivity conferring protein Proteins 0.000 claims description 7
• 230000001953 sensory effect Effects 0.000 claims description 7
• 208000031162 sideroblastic anemia Diseases 0.000 claims description 7
• 201000002569 3-methylglutaconic aciduria type 5 Diseases 0.000 claims description 6
• 201000007993 AGAT deficiency Diseases 0.000 claims description 6
• 208000019932 Aciduria Diseases 0.000 claims description 6
• 208000005676 Adrenogenital syndrome Diseases 0.000 claims description 6
• 108010032178 Amino-acid N-acetyltransferase Proteins 0.000 claims description 6
• 102000007610 Amino-acid N-acetyltransferase Human genes 0.000 claims description 6
• 201000000096 Brunner Syndrome Diseases 0.000 claims description 6
• 108700036915 Brunner Syndrome Proteins 0.000 claims description 6
• 108010068197 Butyryl-CoA Dehydrogenase Proteins 0.000 claims description 6
• 108010066477 Carnitine O-acetyltransferase Proteins 0.000 claims description 6
• 102100036357 Carnitine O-acetyltransferase Human genes 0.000 claims description 6
• 108700017419 Carnitine-Acylcarnitine Translocase Deficiency Proteins 0.000 claims description 6
• 208000008448 Congenital adrenal hyperplasia Diseases 0.000 claims description 6
• 208000026372 Congenital cystic kidney disease Diseases 0.000 claims description 6
• 206010010774 Constipation Diseases 0.000 claims description 6
• 208000004986 Diffuse Cerebral Sclerosis of Schilder Diseases 0.000 claims description 6
• 208000037438 Dilated cardiomyopathy with ataxia Diseases 0.000 claims description 6
• 208000037149 Facioscapulohumeral dystrophy Diseases 0.000 claims description 6
• 206010061159 Foot deformity Diseases 0.000 claims description 6
• 208000021097 Glutaryl-CoA dehydrogenase deficiency Diseases 0.000 claims description 6
• 208000007698 Gyrate Atrophy Diseases 0.000 claims description 6
• 101000942217 Homo sapiens Protein C19orf12 Proteins 0.000 claims description 6
• 208000013016 Hypoglycemia Diseases 0.000 claims description 6
• 208000000420 Isovaleric acidemia Diseases 0.000 claims description 6
• 208000030162 Maple syrup disease Diseases 0.000 claims description 6
• 206010059521 Methylmalonic aciduria Diseases 0.000 claims description 6
• 108010066953 Mitochondrial Trifunctional Protein Proteins 0.000 claims description 6
• 102000018738 Mitochondrial Trifunctional Protein Human genes 0.000 claims description 6
• 108700019255 Mitochondrial complex I deficiency Proteins 0.000 claims description 6
• 208000032696 Monoamine oxidase A deficiency Diseases 0.000 claims description 6
• 208000010428 Muscle Weakness Diseases 0.000 claims description 6
• 206010028372 Muscular weakness Diseases 0.000 claims description 6
• 208000035544 Nonketotic hyperglycinaemia Diseases 0.000 claims description 6
• 101710198224 Ornithine carbamoyltransferase, mitochondrial Proteins 0.000 claims description 6
• 206010068786 Overlap syndrome Diseases 0.000 claims description 6
• 201000002786 Perrault syndrome Diseases 0.000 claims description 6
• 102100032608 Protein C19orf12 Human genes 0.000 claims description 6
• 206010039020 Rhabdomyolysis Diseases 0.000 claims description 6
• 208000018675 Schwartz-Jampel syndrome Diseases 0.000 claims description 6
• 201000003222 Schwartz-Jampel syndrome 1 Diseases 0.000 claims description 6
• 208000036451 Schwartz-Jampel syndrome type 1 Diseases 0.000 claims description 6
• 102100036325 Sterol 26-hydroxylase, mitochondrial Human genes 0.000 claims description 6
• 208000033858 Stüve-Wiedemann syndrome Diseases 0.000 claims description 6
• 208000008206 Talipes Cavus Diseases 0.000 claims description 6
• 208000015441 X-linked distal spinal muscular atrophy 3 Diseases 0.000 claims description 6
• 201000005715 autosomal dominant nonsyndromic deafness 64 Diseases 0.000 claims description 6
• 208000032602 autosomal dominant nonsyndromic hearing loss 64 Diseases 0.000 claims description 6
• 208000019562 autosomal dominant progressive external ophthalmoplegia with mitochondrial DNA deletions 5 Diseases 0.000 claims description 6
• 208000025836 cardioencephalomyopathy Diseases 0.000 claims description 6
• 208000014214 cardiofaciocutaneous syndrome 1 Diseases 0.000 claims description 6
• 208000005071 carnitine-acylcarnitine translocase deficiency Diseases 0.000 claims description 6
• 208000001088 cerebrotendinous xanthomatosis Diseases 0.000 claims description 6
• 208000003895 combined oxidative phosphorylation deficiency 1 Diseases 0.000 claims description 6
• 208000026346 combined oxidative phosphorylation deficiency 10 Diseases 0.000 claims description 6
• 208000026800 combined oxidative phosphorylation deficiency 11 Diseases 0.000 claims description 6
• 208000026850 combined oxidative phosphorylation deficiency 12 Diseases 0.000 claims description 6
• 208000027446 combined oxidative phosphorylation deficiency 13 Diseases 0.000 claims description 6
• 208000026768 combined oxidative phosphorylation deficiency 15 Diseases 0.000 claims description 6
• 208000026855 combined oxidative phosphorylation deficiency 17 Diseases 0.000 claims description 6
• 208000027431 combined oxidative phosphorylation deficiency 19 Diseases 0.000 claims description 6
• 208000003938 combined oxidative phosphorylation deficiency 2 Diseases 0.000 claims description 6
• 208000026427 combined oxidative phosphorylation deficiency 20 Diseases 0.000 claims description 6
• 208000027480 combined oxidative phosphorylation deficiency 21 Diseases 0.000 claims description 6
• 208000003933 combined oxidative phosphorylation deficiency 3 Diseases 0.000 claims description 6
• 208000005089 combined oxidative phosphorylation deficiency 4 Diseases 0.000 claims description 6
• 208000005115 combined oxidative phosphorylation deficiency 5 Diseases 0.000 claims description 6
• 208000017641 combined oxidative phosphorylation deficiency 6 Diseases 0.000 claims description 6
• 208000026798 combined oxidative phosphorylation deficiency 7 Diseases 0.000 claims description 6
• 208000026428 combined oxidative phosphorylation deficiency 8 Diseases 0.000 claims description 6
• 201000008696 deafness-dystonia-optic neuronopathy syndrome Diseases 0.000 claims description 6
• 208000008512 dimethylglycine dehydrogenase deficiency Diseases 0.000 claims description 6
• 208000008570 facioscapulohumeral muscular dystrophy Diseases 0.000 claims description 6
• 206010016165 failure to thrive Diseases 0.000 claims description 6
• 208000011532 familial hyperinsulinism Diseases 0.000 claims description 6
• 201000011205 glycine encephalopathy Diseases 0.000 claims description 6
• 208000015811 hyperuricemia-pulmonary hypertension-renal failure-alkalosis syndrome Diseases 0.000 claims description 6
• 230000002218 hypoglycaemic effect Effects 0.000 claims description 6
• 201000001451 hypomyelinating leukodystrophy Diseases 0.000 claims description 6
• 208000023692 inborn mitochondrial myopathy Diseases 0.000 claims description 6
• 201000008319 inclusion body myositis Diseases 0.000 claims description 6
• 108700036927 isovaleric Acidemia Proteins 0.000 claims description 6
• 201000003723 learning disability Diseases 0.000 claims description 6
• 208000024393 maple syrup urine disease Diseases 0.000 claims description 6
• 230000003340 mental effect Effects 0.000 claims description 6
• 108010071806 methylcrotonoyl-CoA carboxylase Proteins 0.000 claims description 6
• 201000003694 methylmalonic acidemia Diseases 0.000 claims description 6
• 201000011558 mitochondrial DNA depletion syndrome 11 Diseases 0.000 claims description 6
• 208000033274 mitochondrial DNA depletion syndrome 12B (cardiomyopathic type), autosomal recessive Diseases 0.000 claims description 6
• 201000011552 mitochondrial DNA depletion syndrome 2 Diseases 0.000 claims description 6
• 208000001043 mitochondrial complex I deficiency Diseases 0.000 claims description 6
• 201000006825 mitochondrial pyruvate carrier deficiency Diseases 0.000 claims description 6
• 201000011652 multiple mitochondrial dysfunctions syndrome 1 Diseases 0.000 claims description 6
• 201000011658 multiple mitochondrial dysfunctions syndrome 3 Diseases 0.000 claims description 6
• 201000010256 myopathy, lactic acidosis, and sideroblastic anemia Diseases 0.000 claims description 6
• 201000003631 narcolepsy Diseases 0.000 claims description 6
• 201000002648 nephronophthisis Diseases 0.000 claims description 6
• 201000007615 neurodegeneration with brain iron accumulation 4 Diseases 0.000 claims description 6
• 201000006790 nonsyndromic deafness Diseases 0.000 claims description 6
• 230000003647 oxidation Effects 0.000 claims description 6
• 238000007254 oxidation reaction Methods 0.000 claims description 6
• 208000014056 progressive external ophthalmoplegia with mitochondrial DNA deletions Diseases 0.000 claims description 6
• 201000004012 propionic acidemia Diseases 0.000 claims description 6
• 210000002027 skeletal muscle Anatomy 0.000 claims description 6
• 238000001228 spectrum Methods 0.000 claims description 6
• 208000016505 systemic primary carnitine deficiency disease Diseases 0.000 claims description 6
• 206010043554 thrombocytopenia Diseases 0.000 claims description 6
• 201000010866 very long chain acyl-CoA dehydrogenase deficiency Diseases 0.000 claims description 6
• KVZLHPXEUGJPAH-UHFFFAOYSA-N 2-oxidanylpropanoic acid Chemical group CC(O)C(O)=O.CC(O)C(O)=O KVZLHPXEUGJPAH-UHFFFAOYSA-N 0.000 claims description 5
• 208000000044 Amnesia Diseases 0.000 claims description 5
• 206010003084 Areflexia Diseases 0.000 claims description 5
• 208000034523 Ataxia-oculomotor apraxia type 1 Diseases 0.000 claims description 5
• 206010003805 Autism Diseases 0.000 claims description 5
• 208000020706 Autistic disease Diseases 0.000 claims description 5
• 208000035900 Autoimmune polyendocrinopathy type 1 Diseases 0.000 claims description 5
• 206010003840 Autonomic nervous system imbalance Diseases 0.000 claims description 5
• 208000024806 Brain atrophy Diseases 0.000 claims description 5
• 102000002666 Carnitine O-palmitoyltransferase Human genes 0.000 claims description 5
• 201000003679 Charlevoix-Saguenay spastic ataxia Diseases 0.000 claims description 5
• 206010008748 Chorea Diseases 0.000 claims description 5
• 208000018522 Gastrointestinal disease Diseases 0.000 claims description 5
• 101001000545 Homo sapiens Probable hydrolase PNKD Proteins 0.000 claims description 5
• 108700010229 Leukoencephalopathy with Brainstem and Spinal Cord Involvement and Lactate Elevation Proteins 0.000 claims description 5
• 208000025121 Leukoencephalopathy with brain stem and spinal cord involvement-high lactate syndrome Diseases 0.000 claims description 5
• 208000026139 Memory disease Diseases 0.000 claims description 5
• 206010051403 Mitochondrial DNA deletion Diseases 0.000 claims description 5
• 102100027891 Mitochondrial chaperone BCS1 Human genes 0.000 claims description 5
• 206010028980 Neoplasm Diseases 0.000 claims description 5
• 208000003150 Paroxysmal non-kinesigenic dyskinesia Diseases 0.000 claims description 5
• 102100035920 Probable hydrolase PNKD Human genes 0.000 claims description 5
• 208000005392 Spasm Diseases 0.000 claims description 5
• 208000001077 Spastic ataxia Diseases 0.000 claims description 5
• 201000006821 X-linked sideroblastic anemia with ataxia Diseases 0.000 claims description 5
• 230000001919 adrenal effect Effects 0.000 claims description 5
• 208000008784 apnea Diseases 0.000 claims description 5
• 201000006797 autosomal dominant nonsyndromic deafness Diseases 0.000 claims description 5
• 208000012601 choreatic disease Diseases 0.000 claims description 5
• 208000004209 confusion Diseases 0.000 claims description 5
• 230000002950 deficient Effects 0.000 claims description 5
• 206010013395 disorientation Diseases 0.000 claims description 5
• 230000004438 eyesight Effects 0.000 claims description 5
• 206010016256 fatigue Diseases 0.000 claims description 5
• 208000013967 frontotemporal dementia and/or amyotrophic lateral sclerosis 1 Diseases 0.000 claims description 5
• 208000019622 heart disease Diseases 0.000 claims description 5
• 208000017169 kidney disease Diseases 0.000 claims description 5
• 208000022618 left ventricular noncompaction 1 Diseases 0.000 claims description 5
• 230000006984 memory degeneration Effects 0.000 claims description 5
• 208000023060 memory loss Diseases 0.000 claims description 5
• 208000030159 metabolic disease Diseases 0.000 claims description 5
• 230000022886 mitochondrial translation Effects 0.000 claims description 5
• 208000023055 multiple mitochondrial dysfunctions syndrome 2 Diseases 0.000 claims description 5
• 230000007971 neurological deficit Effects 0.000 claims description 5
• 208000014380 ornithine aminotransferase deficiency Diseases 0.000 claims description 5
• 201000001506 primary coenzyme Q10 deficiency 1 Diseases 0.000 claims description 5
• 230000009747 swallowing Effects 0.000 claims description 5
• 230000006016 thyroid dysfunction Effects 0.000 claims description 5
• 208000010444 Acidosis Diseases 0.000 claims description 4
• 208000013381 GRACILE syndrome Diseases 0.000 claims description 4
• 206010058359 Hypogonadism Diseases 0.000 claims description 4
• 208000009564 MELAS Syndrome Diseases 0.000 claims description 4
• 108700033252 Mitochondrial Complex III Deficiency Proteins 0.000 claims description 4
• 208000013233 NARP syndrome Diseases 0.000 claims description 4
• 239000001569 carbon dioxide Substances 0.000 claims description 4
• 229910002092 carbon dioxide Inorganic materials 0.000 claims description 4
• 208000000188 mitochondrial complex III deficiency Diseases 0.000 claims description 4
• 230000036284 oxygen consumption Effects 0.000 claims description 4
• 229950007002 phosphocreatine Drugs 0.000 claims description 4
• 201000003036 pontocerebellar hypoplasia type 6 Diseases 0.000 claims description 4
• 239000003642 reactive oxygen metabolite Substances 0.000 claims description 4
• 208000005809 status epilepticus Diseases 0.000 claims description 4
• VNOYUJKHFWYWIR-ITIYDSSPSA-N succinyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CCC(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 VNOYUJKHFWYWIR-ITIYDSSPSA-N 0.000 claims description 4
• 239000003053 toxin Substances 0.000 claims description 4
• 231100000765 toxin Toxicity 0.000 claims description 4
• 108700012359 toxins Proteins 0.000 claims description 4
• 108700032300 2,4-Dienoyl-CoA Reductase Deficiency Proteins 0.000 claims description 3
• 201000006753 2-hydroxyglutaric aciduria Diseases 0.000 claims description 3
• HWKRAUXFMLQKLS-UHFFFAOYSA-N 2-oxidanylidenepropanoic acid Chemical compound CC(=O)C(O)=O.CC(=O)C(O)=O HWKRAUXFMLQKLS-UHFFFAOYSA-N 0.000 claims description 3
• 108700005239 3-Hydroxyacyl-CoA Dehydrogenase Deficiency Proteins 0.000 claims description 3
• 208000010768 3-hydroxy-3-methylglutaryl-CoA synthase deficiency Diseases 0.000 claims description 3
• 208000009270 3-hydroxyacyl-CoA dehydrogenase deficiency Diseases 0.000 claims description 3
• 102100034767 3-hydroxyisobutyryl-CoA hydrolase, mitochondrial Human genes 0.000 claims description 3
• 201000002568 3-methylglutaconic aciduria with deafness, encephalopathy, and Leigh-like syndrome Diseases 0.000 claims description 3
• 208000013824 Acidemia Diseases 0.000 claims description 3
• 208000026872 Addison Disease Diseases 0.000 claims description 3
• 208000031212 Autoimmune polyendocrinopathy Diseases 0.000 claims description 3
• 208000022106 Autoimmune polyendocrinopathy type 2 Diseases 0.000 claims description 3
• 208000015012 Autosomal recessive progressive external ophthalmoplegia Diseases 0.000 claims description 3
• 206010006895 Cachexia Diseases 0.000 claims description 3
• 208000004894 Camptocormia Diseases 0.000 claims description 3
• 102100036372 Carbonic anhydrase 5A, mitochondrial Human genes 0.000 claims description 3
• 101710133954 Carbonic anhydrase 5A, mitochondrial Proteins 0.000 claims description 3
• 102100027943 Carnitine O-palmitoyltransferase 1, liver isoform Human genes 0.000 claims description 3
• 101710120614 Carnitine O-palmitoyltransferase 1, liver isoform Proteins 0.000 claims description 3
• 101710108984 Carnitine O-palmitoyltransferase 1, muscle isoform Proteins 0.000 claims description 3
• 206010058892 Carnitine deficiency Diseases 0.000 claims description 3
• 201000002929 Carnitine palmitoyltransferase II deficiency Diseases 0.000 claims description 3
• 208000004918 Cartilage-hair hypoplasia Diseases 0.000 claims description 3
• 208000027935 Cataract-growth hormone deficiency-sensory neuropathy-sensorineural hearing loss-skeletal dysplasia syndrome Diseases 0.000 claims description 3
• 206010053684 Cerebrohepatorenal syndrome Diseases 0.000 claims description 3
• 241000601170 Clematis lasiantha Species 0.000 claims description 3
• 208000037125 Congenital cataract-hypertrophic cardiomyopathy-mitochondrial myopathy syndrome Diseases 0.000 claims description 3
• 102000004420 Creatine Kinase Human genes 0.000 claims description 3
• 108010042126 Creatine kinase Proteins 0.000 claims description 3
• 230000007035 DNA breakage Effects 0.000 claims description 3
• 206010014952 Eosinophilia myalgia syndrome Diseases 0.000 claims description 3
• 206010014954 Eosinophilic fasciitis Diseases 0.000 claims description 3
• 208000003613 Ethylmalonic encephalopathy Diseases 0.000 claims description 3
• 208000018137 Extraocular muscle disease Diseases 0.000 claims description 3
• 208000014887 Focal myositis Diseases 0.000 claims description 3
• 208000006517 Fumaric aciduria Diseases 0.000 claims description 3
• 108700036912 Fumaric aciduria Proteins 0.000 claims description 3
• 229920002527 Glycogen Polymers 0.000 claims description 3
• 208000009329 Graft vs Host Disease Diseases 0.000 claims description 3
• 208000036066 Hemophagocytic Lymphohistiocytosis Diseases 0.000 claims description 3
• 208000002972 Hepatolenticular Degeneration Diseases 0.000 claims description 3
• 208000032672 Histiocytosis haematophagic Diseases 0.000 claims description 3
• 206010020575 Hyperammonaemia Diseases 0.000 claims description 3
• 208000037147 Hypercalcaemia Diseases 0.000 claims description 3
• 208000012528 Juvenile dermatomyositis Diseases 0.000 claims description 3
• 201000009342 Limb-girdle muscular dystrophy Diseases 0.000 claims description 3
• 208000017170 Lipid metabolism disease Diseases 0.000 claims description 3
• 208000002447 Macrophagic myofasciitis Diseases 0.000 claims description 3
• 208000018717 Malignant hyperthermia of anesthesia Diseases 0.000 claims description 3
• 208000008948 Menkes Kinky Hair Syndrome Diseases 0.000 claims description 3
• 208000012583 Menkes disease Diseases 0.000 claims description 3
• 108700033011 Mitochondrial Complex II Deficiency Proteins 0.000 claims description 3
• 208000035760 Mitochondrial DNA-related mitochondrial myopathy Diseases 0.000 claims description 3
• 108700039684 Mitochondrial Phosphate Carrier Deficiency Proteins 0.000 claims description 3
• 208000000475 Mohr-Tranebjaerg syndrome Diseases 0.000 claims description 3
• 208000001769 Multiple Acyl Coenzyme A Dehydrogenase Deficiency Diseases 0.000 claims description 3
• 208000000112 Myalgia Diseases 0.000 claims description 3
• 208000013928 Myopathy and diabetes mellitus Diseases 0.000 claims description 3
• 206010028665 Myxoedema Diseases 0.000 claims description 3
• 206010029350 Neurotoxicity Diseases 0.000 claims description 3
• 208000004931 Orbital Myositis Diseases 0.000 claims description 3
• 206010033165 Ovarian failure Diseases 0.000 claims description 3
• 208000005746 Phosphoenolpyruvate carboxykinase deficiency Diseases 0.000 claims description 3
• 208000030464 Postaxial acrofacial dysostosis Diseases 0.000 claims description 3
• 208000028269 Progressive encephalopathy with leukodystrophy due to DECR deficiency Diseases 0.000 claims description 3
• 208000021886 Pyruvate carboxylase deficiency Diseases 0.000 claims description 3
• 208000001821 Pyruvate dehydrogenase E3-binding protein deficiency Diseases 0.000 claims description 3
• 108700042837 Pyruvate dehydrogenase phosphatase deficiency Proteins 0.000 claims description 3
• 208000008144 Rigid spine syndrome Diseases 0.000 claims description 3
• 206010039921 Selenium deficiency Diseases 0.000 claims description 3
• 201000011655 Sengers syndrome Diseases 0.000 claims description 3
• 102100036924 Solute carrier family 22 member 5 Human genes 0.000 claims description 3
• 208000033897 Systemic primary carnitine deficiency Diseases 0.000 claims description 3
• 206010044221 Toxic encephalopathy Diseases 0.000 claims description 3
• 102000004357 Transferases Human genes 0.000 claims description 3
• 108090000992 Transferases Proteins 0.000 claims description 3
• XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical group ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 claims description 3
• 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims description 3
• 208000018839 Wilson disease Diseases 0.000 claims description 3
• 208000013035 X-linked distal spinal muscular atrophy type 3 Diseases 0.000 claims description 3
• 201000004525 Zellweger Syndrome Diseases 0.000 claims description 3
• 208000036813 Zellweger spectrum disease Diseases 0.000 claims description 3
• 208000033017 acquired idiopathic inflammatory myopathy Diseases 0.000 claims description 3
• 230000002529 anti-mitochondrial effect Effects 0.000 claims description 3
• GOLCXWYRSKYTSP-UHFFFAOYSA-N arsenic trioxide Inorganic materials O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 claims description 3
• 230000001363 autoimmune Effects 0.000 claims description 3
• 201000009780 autoimmune polyendocrine syndrome type 2 Diseases 0.000 claims description 3
• 208000012892 autosomal dominant progressive external ophthalmoplegia Diseases 0.000 claims description 3
• 208000019478 autosomal dominant progressive external ophthalmoplegia with mitochondrial DNA deletions 6 Diseases 0.000 claims description 3
• 208000019481 autosomal dominant progressive external ophthalmoplegia with mitochondrial DNA deletions 3 Diseases 0.000 claims description 3
• 208000020040 autosomal dominant progressive external ophthalmoplegia with mitochondrial DNA deletions 4 Diseases 0.000 claims description 3
• 108010064675 calcium dependent sulfhydryl protease Proteins 0.000 claims description 3
• 208000015114 central nervous system disease Diseases 0.000 claims description 3
• KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 claims description 3
• 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims description 3
• 210000002808 connective tissue Anatomy 0.000 claims description 3
• 230000003210 demyelinating effect Effects 0.000 claims description 3
• 208000021814 developmental and epileptic encephalopathy 3 Diseases 0.000 claims description 3
• 235000014113 dietary fatty acids Nutrition 0.000 claims description 3
• 201000009338 distal myopathy Diseases 0.000 claims description 3
• 208000008965 epilepsia partialis continua Diseases 0.000 claims description 3
• 201000007089 exocrine pancreatic insufficiency Diseases 0.000 claims description 3
• 201000010934 exostosis Diseases 0.000 claims description 3
• 208000008836 familial idiopathic inflammatory myopathy Diseases 0.000 claims description 3
• 229930195729 fatty acid Natural products 0.000 claims description 3
• 239000000194 fatty acid Substances 0.000 claims description 3
• 150000004665 fatty acids Chemical class 0.000 claims description 3
• 208000014346 fumarase deficiency Diseases 0.000 claims description 3
• 229910052732 germanium Inorganic materials 0.000 claims description 3
• GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 claims description 3
• 229940096919 glycogen Drugs 0.000 claims description 3
• 208000024908 graft versus host disease Diseases 0.000 claims description 3
• 208000037824 growth disorder Diseases 0.000 claims description 3
• 208000014752 hemophagocytic syndrome Diseases 0.000 claims description 3
• 208000014471 histiocytoid cardiomyopathy Diseases 0.000 claims description 3
• 230000000148 hypercalcaemia Effects 0.000 claims description 3
• 208000030915 hypercalcemia disease Diseases 0.000 claims description 3
• 201000010930 hyperostosis Diseases 0.000 claims description 3
• 230000000396 hypokalemic effect Effects 0.000 claims description 3
• 201000001372 immunodeficiency with hyper IgM type 5 Diseases 0.000 claims description 3
• 208000014674 injury Diseases 0.000 claims description 3
• 208000028867 ischemia Diseases 0.000 claims description 3
• 208000029621 linear skin defects with multiple congenital anomalies 1 Diseases 0.000 claims description 3
• 208000013479 maternally-inherited mitochondrial myopathy Diseases 0.000 claims description 3
• 201000006961 megaconial type congenital muscular dystrophy Diseases 0.000 claims description 3
• 208000005135 methemoglobinemia Diseases 0.000 claims description 3
• 201000011543 mitochondrial DNA depletion syndrome 3 Diseases 0.000 claims description 3
• 201000011563 mitochondrial DNA depletion syndrome 9 Diseases 0.000 claims description 3
• 208000010685 mitochondrial complex 5 (ATP synthase) deficiency nuclear type 5 Diseases 0.000 claims description 3
• 208000007945 mitochondrial complex II deficiency Diseases 0.000 claims description 3
• 201000001101 mitochondrial complex V (ATP synthase) deficiency Diseases 0.000 claims description 3
• 201000008670 mitochondrial complex V (ATP synthase) deficiency, nuclear type 1 Diseases 0.000 claims description 3
• 230000010021 mitochondrial pathology Effects 0.000 claims description 3
• 208000024933 mitochondrial proton-transporting ATP synthase complex deficiency Diseases 0.000 claims description 3
• 201000003645 multiple acyl-CoA dehydrogenase deficiency Diseases 0.000 claims description 3
• 208000002288 myopathic carnitine deficiency Diseases 0.000 claims description 3
• 208000003786 myxedema Diseases 0.000 claims description 3
• 230000002956 necrotizing effect Effects 0.000 claims description 3
• 231100000228 neurotoxicity Toxicity 0.000 claims description 3
• 230000007135 neurotoxicity Effects 0.000 claims description 3
• 208000033031 nuclear type 1 mitochondrial complex II deficiency Diseases 0.000 claims description 3
• 229940127073 nucleoside analogue Drugs 0.000 claims description 3
• 208000007064 occipital horn syndrome Diseases 0.000 claims description 3
• 201000010668 orbital plasma cell granuloma Diseases 0.000 claims description 3
• 201000007976 ornithine translocase deficiency Diseases 0.000 claims description 3
• 201000004535 ovarian dysfunction Diseases 0.000 claims description 3
• 231100000539 ovarian failure Toxicity 0.000 claims description 3
• 229910052760 oxygen Inorganic materials 0.000 claims description 3
• 230000000737 periodic effect Effects 0.000 claims description 3
• 208000005987 polymyositis Diseases 0.000 claims description 3
• 201000001530 primary coenzyme Q10 deficiency 6 Diseases 0.000 claims description 3
• 208000003903 pyruvate dehydrogenase phosphatase deficiency Diseases 0.000 claims description 3
• 201000007153 reticular dysgenesis Diseases 0.000 claims description 3
• 230000002441 reversible effect Effects 0.000 claims description 3
• 201000006956 rigid spine muscular dystrophy 1 Diseases 0.000 claims description 3
• 208000002477 septooptic dysplasia Diseases 0.000 claims description 3
• AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 claims description 3
• 208000002320 spinal muscular atrophy Diseases 0.000 claims description 3
• 230000009885 systemic effect Effects 0.000 claims description 3
• 231100000331 toxic Toxicity 0.000 claims description 3
• 230000002588 toxic effect Effects 0.000 claims description 3
• 230000008733 trauma Effects 0.000 claims description 3
• UBOXGVDOUJQMTN-UHFFFAOYSA-N trichloroethylene Natural products ClCC(Cl)Cl UBOXGVDOUJQMTN-UHFFFAOYSA-N 0.000 claims description 3
• 102000003298 tumor necrosis factor receptor Human genes 0.000 claims description 3
• 229940102566 valproate Drugs 0.000 claims description 3
• WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical compound CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 claims 4
• 208000035172 MERRF Diseases 0.000 claims 2
• 102000007981 Ornithine carbamoyltransferase Human genes 0.000 claims 2
• 108700013829 Pyruvate Dehydrogenase E1 Alpha Deficiency Proteins 0.000 claims 2
• 208000000008 pyruvate dehydrogenase E1-alpha deficiency Diseases 0.000 claims 2
• 208000008382 pyruvate dehydrogenase E1-beta deficiency Diseases 0.000 claims 2
• 208000014855 vitamin D-dependent rickets type 1A Diseases 0.000 claims 2
• HJTAZXHBEBIQQX-UHFFFAOYSA-N 1,5-bis(chloromethyl)naphthalene Chemical compound C1=CC=C2C(CCl)=CC=CC2=C1CCl HJTAZXHBEBIQQX-UHFFFAOYSA-N 0.000 claims 1
• 102100021822 Enoyl-CoA hydratase, mitochondrial Human genes 0.000 claims 1
• 101710180035 Enoyl-CoA hydratase, mitochondrial Proteins 0.000 claims 1
• 101000872461 Homo sapiens 3-hydroxyisobutyryl-CoA hydrolase, mitochondrial Proteins 0.000 claims 1
• 208000035177 MELAS Diseases 0.000 claims 1
• 208000014844 Mitochondrial neurogastrointestinal encephalomyopathy Diseases 0.000 claims 1
• 208000027919 Sensory ataxic neuropathy-dysarthria-ophthalmoparesis syndrome Diseases 0.000 claims 1
• 208000019880 recessive mitochondrial ataxia syndrome Diseases 0.000 claims 1
• 208000002916 sensory ataxic neuropathy, dysarthria, and ophthalmoparesis Diseases 0.000 claims 1
• 238000005516 engineering process Methods 0.000 abstract description 33
• 238000011282 treatment Methods 0.000 abstract description 13
• 125000000217 alkyl group Chemical group 0.000 description 93
• 230000035772 mutation Effects 0.000 description 92
• 239000000460 chlorine Substances 0.000 description 65
• 125000003118 aryl group Chemical group 0.000 description 51
• 108090000623 proteins and genes Proteins 0.000 description 51
• 125000003342 alkenyl group Chemical group 0.000 description 39
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 33
• 208000035475 disorder Diseases 0.000 description 32
• 125000000753 cycloalkyl group Chemical group 0.000 description 31
• 239000012528 membrane Substances 0.000 description 31
• 210000004379 membrane Anatomy 0.000 description 30
• 125000004432 carbon atom Chemical group C* 0.000 description 23
• 230000000149 penetrating effect Effects 0.000 description 23
• 150000001768 cations Chemical class 0.000 description 22
• 125000000623 heterocyclic group Chemical group 0.000 description 20
• 229940024606 amino acid Drugs 0.000 description 19
• 150000001413 amino acids Chemical class 0.000 description 19
• 230000002490 cerebral effect Effects 0.000 description 19
• 210000001175 cerebrospinal fluid Anatomy 0.000 description 19
• 235000018102 proteins Nutrition 0.000 description 19
• 102000004169 proteins and genes Human genes 0.000 description 19
• LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 18
• 235000001014 amino acid Nutrition 0.000 description 18
• 210000004369 blood Anatomy 0.000 description 18
• 239000008280 blood Substances 0.000 description 18
• 125000000304 alkynyl group Chemical group 0.000 description 17
• 150000004059 quinone derivatives Chemical class 0.000 description 17
• 125000003710 aryl alkyl group Chemical group 0.000 description 16
• 210000004027 cell Anatomy 0.000 description 15
• 239000000835 fiber Substances 0.000 description 15
• 239000012530 fluid Substances 0.000 description 14
• 208000015122 neurodegenerative disease Diseases 0.000 description 14
• 210000002381 plasma Anatomy 0.000 description 14
• 230000002861 ventricular Effects 0.000 description 14
• 239000001257 hydrogen Substances 0.000 description 13
• 125000000962 organic group Chemical group 0.000 description 13
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 12
• 108020004566 Transfer RNA Proteins 0.000 description 12
• 208000027014 optic atrophy 1 Diseases 0.000 description 12
• 230000005856 abnormality Effects 0.000 description 11
• 230000000694 effects Effects 0.000 description 11
• 125000004415 heterocyclylalkyl group Chemical group 0.000 description 11
• 102000010909 Monoamine Oxidase Human genes 0.000 description 10
• 108010062431 Monoamine oxidase Proteins 0.000 description 10
• 229910052757 nitrogen Inorganic materials 0.000 description 10
• 108090000765 processed proteins & peptides Proteins 0.000 description 10
• 230000004393 visual impairment Effects 0.000 description 10
• 201000009035 MERRF syndrome Diseases 0.000 description 9
• 208000008238 Muscle Spasticity Diseases 0.000 description 9
• 239000002773 nucleotide Substances 0.000 description 9
• 125000003729 nucleotide group Chemical group 0.000 description 9
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 9
• 239000000523 sample Substances 0.000 description 9
• 238000012360 testing method Methods 0.000 description 9
• 201000004569 Blindness Diseases 0.000 description 8
• 206010013887 Dysarthria Diseases 0.000 description 8
• 125000001072 heteroaryl group Chemical group 0.000 description 8
• 125000005842 heteroatom Chemical group 0.000 description 8
• 210000004698 lymphocyte Anatomy 0.000 description 8
• 210000001700 mitochondrial membrane Anatomy 0.000 description 8
• 102000004196 processed proteins & peptides Human genes 0.000 description 8
• 125000001424 substituent group Chemical group 0.000 description 8
• 230000000007 visual effect Effects 0.000 description 8
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 7
• 206010003694 Atrophy Diseases 0.000 description 7
• 206010008027 Cerebellar atrophy Diseases 0.000 description 7
• 102000004190 Enzymes Human genes 0.000 description 7
• 108090000790 Enzymes Proteins 0.000 description 7
• 208000006011 Stroke Diseases 0.000 description 7
• 239000004480 active ingredient Substances 0.000 description 7
• 230000037444 atrophy Effects 0.000 description 7
• 230000015572 biosynthetic process Effects 0.000 description 7
• 210000004556 brain Anatomy 0.000 description 7
• 230000007547 defect Effects 0.000 description 7
• 229940088598 enzyme Drugs 0.000 description 7
• 150000002431 hydrogen Chemical group 0.000 description 7
• 230000008811 mitochondrial respiratory chain Effects 0.000 description 7
• 206010030875 ophthalmoplegia Diseases 0.000 description 7
• 230000035806 respiratory chain Effects 0.000 description 7
• 208000018198 spasticity Diseases 0.000 description 7
• 210000001519 tissue Anatomy 0.000 description 7
• 125000006710 (C2-C12) alkenyl group Chemical group 0.000 description 6
• 125000006711 (C2-C12) alkynyl group Chemical group 0.000 description 6
• GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 6
• KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 6
• 108020004414 DNA Proteins 0.000 description 6
• 101710088194 Dehydrogenase Proteins 0.000 description 6
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 6
• XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 6
• 229910000147 aluminium phosphate Inorganic materials 0.000 description 6
• ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 6
• 230000002068 genetic effect Effects 0.000 description 6
• 230000010370 hearing loss Effects 0.000 description 6
• 231100000888 hearing loss Toxicity 0.000 description 6
• 108020004999 messenger RNA Proteins 0.000 description 6
• 238000001964 muscle biopsy Methods 0.000 description 6
• 230000004770 neurodegeneration Effects 0.000 description 6
• 210000001328 optic nerve Anatomy 0.000 description 6
• 229920001184 polypeptide Polymers 0.000 description 6
• 230000011514 reflex Effects 0.000 description 6
• 210000003994 retinal ganglion cell Anatomy 0.000 description 6
• 239000011669 selenium Substances 0.000 description 6
• 210000004885 white matter Anatomy 0.000 description 6
• 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 5
• 102100024044 Aprataxin Human genes 0.000 description 5
• ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 5
• PTPHDVKWAYIFRX-UHFFFAOYSA-N Palmatine Natural products C1C2=C(OC)C(OC)=CC=C2C=C2N1CCC1=C2C=C(OC)C(OC)=C1 PTPHDVKWAYIFRX-UHFFFAOYSA-N 0.000 description 5
• YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 5
• QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 5
• 229940093265 berberine Drugs 0.000 description 5
• 230000037430 deletion Effects 0.000 description 5
• 238000012217 deletion Methods 0.000 description 5
• 238000011161 development Methods 0.000 description 5
• 230000018109 developmental process Effects 0.000 description 5
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
• 238000004519 manufacturing process Methods 0.000 description 5
• QUCQEUCGKKTEBI-UHFFFAOYSA-N palmatine Chemical compound COC1=CC=C2C=C(C3=C(C=C(C(=C3)OC)OC)CC3)[N+]3=CC2=C1OC QUCQEUCGKKTEBI-UHFFFAOYSA-N 0.000 description 5
• 239000002904 solvent Substances 0.000 description 5
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
• AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 4
• WHBMMWSBFZVSSR-UHFFFAOYSA-M 3-hydroxybutyrate Chemical compound CC(O)CC([O-])=O WHBMMWSBFZVSSR-UHFFFAOYSA-M 0.000 description 4
• 101710105690 Aprataxin Proteins 0.000 description 4
• 102100024853 Carnitine O-palmitoyltransferase 2, mitochondrial Human genes 0.000 description 4
• 206010015727 Extensor plantar response Diseases 0.000 description 4
• 206010016654 Fibrosis Diseases 0.000 description 4
• 208000036700 Oculomotor apraxia Diseases 0.000 description 4
• 102100028200 Ornithine transcarbamylase, mitochondrial Human genes 0.000 description 4
• 208000018737 Parkinson disease Diseases 0.000 description 4
• 206010039729 Scotoma Diseases 0.000 description 4
• 102100026508 Tafazzin Human genes 0.000 description 4
• 230000009286 beneficial effect Effects 0.000 description 4
• 230000027455 binding Effects 0.000 description 4
• 239000003795 chemical substances by application Substances 0.000 description 4
• 208000010877 cognitive disease Diseases 0.000 description 4
• 125000004122 cyclic group Chemical group 0.000 description 4
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 4
• 230000034994 death Effects 0.000 description 4
• 230000003247 decreasing effect Effects 0.000 description 4
• 230000006735 deficit Effects 0.000 description 4
• 230000007850 degeneration Effects 0.000 description 4
• 230000003111 delayed effect Effects 0.000 description 4
• VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
• 210000001508 eye Anatomy 0.000 description 4
• 125000005843 halogen group Chemical group 0.000 description 4
• 125000005647 linker group Chemical group 0.000 description 4
• 210000004185 liver Anatomy 0.000 description 4
• 238000012423 maintenance Methods 0.000 description 4
• 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 4
• 230000004065 mitochondrial dysfunction Effects 0.000 description 4
• 230000006705 mitochondrial oxidative phosphorylation Effects 0.000 description 4
• 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 4
• 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 4
• 230000002265 prevention Effects 0.000 description 4
• 230000008569 process Effects 0.000 description 4
• NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 4
• QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
• 210000002435 tendon Anatomy 0.000 description 4
• 125000003944 tolyl group Chemical group 0.000 description 4
• 230000004102 tricarboxylic acid cycle Effects 0.000 description 4
• 229940035936 ubiquinone Drugs 0.000 description 4
• 125000004400 (C1-C12) alkyl group Chemical group 0.000 description 3
• ZTKQHJHANLVEBM-UHFFFAOYSA-N 2-[3-(ethylamino)-6-ethylimino-2,7-dimethylxanthen-9-yl]benzoic acid Chemical compound C1=2C=C(C)C(NCC)=CC=2OC2=CC(=NCC)C(C)=CC2=C1C1=CC=CC=C1C(O)=O ZTKQHJHANLVEBM-UHFFFAOYSA-N 0.000 description 3
• PVSAPJKDKFIKHM-UHFFFAOYSA-N 3-hydroxy-3-methyl-4-(trimethylazaniumyl)butanoate Chemical compound [O-]C(=O)CC(O)(C)C[N+](C)(C)C PVSAPJKDKFIKHM-UHFFFAOYSA-N 0.000 description 3
• 208000000187 Abnormal Reflex Diseases 0.000 description 3
• 238000006412 Alper carbonylation reaction Methods 0.000 description 3
• 208000024827 Alzheimer disease Diseases 0.000 description 3
• 206010001939 Aminoaciduria Diseases 0.000 description 3
• QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 3
• 102100026198 Aspartate-tRNA ligase, mitochondrial Human genes 0.000 description 3
• 206010003594 Ataxia telangiectasia Diseases 0.000 description 3
• 208000034320 Autosomal recessive spastic ataxia of Charlevoix-Saguenay Diseases 0.000 description 3
• 208000005977 Bjornstad syndrome Diseases 0.000 description 3
• 208000028698 Cognitive impairment Diseases 0.000 description 3
• 206010056370 Congestive cardiomyopathy Diseases 0.000 description 3
• 201000010046 Dilated cardiomyopathy Diseases 0.000 description 3
• 101100519466 Drosophila melanogaster mtDNA-helicase gene Proteins 0.000 description 3
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
• 206010015995 Eyelid ptosis Diseases 0.000 description 3
• 208000005622 Gait Ataxia Diseases 0.000 description 3
• 101001109052 Homo sapiens NADH-ubiquinone oxidoreductase chain 4 Proteins 0.000 description 3
• 101000632623 Homo sapiens NADH-ubiquinone oxidoreductase chain 6 Proteins 0.000 description 3
• 101000835595 Homo sapiens Tafazzin Proteins 0.000 description 3
• 208000036626 Mental retardation Diseases 0.000 description 3
• 102100025860 Methionine-tRNA ligase, mitochondrial Human genes 0.000 description 3
• 208000036572 Myoclonic epilepsy Diseases 0.000 description 3
• 102100021506 NADH-ubiquinone oxidoreductase chain 4 Human genes 0.000 description 3
• 102100028386 NADH-ubiquinone oxidoreductase chain 6 Human genes 0.000 description 3
• 108091093105 Nuclear DNA Proteins 0.000 description 3
• 206010061323 Optic neuropathy Diseases 0.000 description 3
• 206010033546 Pallor Diseases 0.000 description 3
• 206010033885 Paraparesis Diseases 0.000 description 3
• FKUYMLZIRPABFK-UHFFFAOYSA-N Plastoquinone 9 Natural products CC(C)=CCCC(C)=CCCC(C)=CCCC(C)=CCCC(C)=CCCC(C)=CCCC(C)=CCCC(C)=CCCC(C)=CCC1=CC(=O)C(C)=C(C)C1=O FKUYMLZIRPABFK-UHFFFAOYSA-N 0.000 description 3
• 102100034272 Sacsin Human genes 0.000 description 3
• 101710102928 Sacsin Proteins 0.000 description 3
• 206010040030 Sensory loss Diseases 0.000 description 3
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
• 208000002548 Spastic Paraparesis Diseases 0.000 description 3
• 101150017595 TTC19 gene Proteins 0.000 description 3
• 206010047571 Visual impairment Diseases 0.000 description 3
• 229930003427 Vitamin E Natural products 0.000 description 3
• 230000035508 accumulation Effects 0.000 description 3
• 238000009825 accumulation Methods 0.000 description 3
• 150000007824 aliphatic compounds Chemical class 0.000 description 3
• 125000001931 aliphatic group Chemical group 0.000 description 3
• 125000002877 alkyl aryl group Chemical group 0.000 description 3
• 230000004075 alteration Effects 0.000 description 3
• 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 3
• 230000006907 apoptotic process Effects 0.000 description 3
• 206010003882 axonal neuropathy Diseases 0.000 description 3
• 230000002146 bilateral effect Effects 0.000 description 3
• 230000005540 biological transmission Effects 0.000 description 3
• 235000020958 biotin Nutrition 0.000 description 3
• 239000011616 biotin Substances 0.000 description 3
• 229960002685 biotin Drugs 0.000 description 3
• 235000010290 biphenyl Nutrition 0.000 description 3
• 239000004305 biphenyl Substances 0.000 description 3
• 210000001185 bone marrow Anatomy 0.000 description 3
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
• 230000000747 cardiac effect Effects 0.000 description 3
• 210000001638 cerebellum Anatomy 0.000 description 3
• 230000008859 change Effects 0.000 description 3
• 208000019425 cirrhosis of liver Diseases 0.000 description 3
• 239000013068 control sample Substances 0.000 description 3
• 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 3
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
• OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 3
• 230000007423 decrease Effects 0.000 description 3
• LUKKCEVNUJBTRF-UHFFFAOYSA-N decyl(triphenyl)phosphanium Chemical compound C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(CCCCCCCCCC)C1=CC=CC=C1 LUKKCEVNUJBTRF-UHFFFAOYSA-N 0.000 description 3
• 238000003745 diagnosis Methods 0.000 description 3
• 235000005911 diet Nutrition 0.000 description 3
• 238000009826 distribution Methods 0.000 description 3
• 229940079593 drug Drugs 0.000 description 3
• 201000009028 early myoclonic encephalopathy Diseases 0.000 description 3
• 230000000763 evoking effect Effects 0.000 description 3
• 238000005755 formation reaction Methods 0.000 description 3
• WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 3
• 229910052736 halogen Inorganic materials 0.000 description 3
• 150000002367 halogens Chemical class 0.000 description 3
• 206010020745 hyperreflexia Diseases 0.000 description 3
• 230000035859 hyperreflexia Effects 0.000 description 3
• 238000003780 insertion Methods 0.000 description 3
• 230000037431 insertion Effects 0.000 description 3
• 229910052742 iron Inorganic materials 0.000 description 3
• 201000004300 left ventricular noncompaction Diseases 0.000 description 3
• 210000002414 leg Anatomy 0.000 description 3
• 101150036750 mars2 gene Proteins 0.000 description 3
• 239000002207 metabolite Substances 0.000 description 3
• 230000011987 methylation Effects 0.000 description 3
• 238000007069 methylation reaction Methods 0.000 description 3
• 125000004433 nitrogen atom Chemical group N* 0.000 description 3
• 238000010606 normalization Methods 0.000 description 3
• 208000020911 optic nerve disease Diseases 0.000 description 3
• 230000008506 pathogenesis Effects 0.000 description 3
• 150000003904 phospholipids Chemical class 0.000 description 3
• FKUYMLZIRPABFK-IQSNHBBHSA-N plastoquinone-9 Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC1=CC(=O)C(C)=C(C)C1=O FKUYMLZIRPABFK-IQSNHBBHSA-N 0.000 description 3
• 230000035755 proliferation Effects 0.000 description 3
• 201000003004 ptosis Diseases 0.000 description 3
• 230000009467 reduction Effects 0.000 description 3
• 230000002207 retinal effect Effects 0.000 description 3
• 210000002966 serum Anatomy 0.000 description 3
• 239000000126 substance Substances 0.000 description 3
• 125000003107 substituted aryl group Chemical group 0.000 description 3
• 125000005346 substituted cycloalkyl group Chemical group 0.000 description 3
• 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 description 3
• 230000002123 temporal effect Effects 0.000 description 3
• 238000012546 transfer Methods 0.000 description 3
• 230000007704 transition Effects 0.000 description 3
• IMFACGCPASFAPR-UHFFFAOYSA-O tributylazanium Chemical compound CCCC[NH+](CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-O 0.000 description 3
• 208000029257 vision disease Diseases 0.000 description 3
• 235000019165 vitamin E Nutrition 0.000 description 3
• 229940046009 vitamin E Drugs 0.000 description 3
• 239000011709 vitamin E Substances 0.000 description 3
• 150000003722 vitamin derivatives Chemical class 0.000 description 3
• PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 2
• 108010046716 3-Methyl-2-Oxobutanoate Dehydrogenase (Lipoamide) Proteins 0.000 description 2
• 108010077268 3-hydroxyisobutyryl-CoA hydrolase Proteins 0.000 description 2
• 102100027451 4-hydroxybenzoate polyprenyltransferase, mitochondrial Human genes 0.000 description 2
• 101710135983 AFG3-like protein 2 Proteins 0.000 description 2
• 230000002407 ATP formation Effects 0.000 description 2
• 102000009836 Aconitate hydratase Human genes 0.000 description 2
• 108010009924 Aconitate hydratase Proteins 0.000 description 2
• 101150118561 Afg3l2 gene Proteins 0.000 description 2
• 206010001488 Aggression Diseases 0.000 description 2
• QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
• 206010002065 Anaemia megaloblastic Diseases 0.000 description 2
• 108010065272 Aspartate-tRNA ligase Proteins 0.000 description 2
• 208000004724 Ataxia neuropathy spectrum Diseases 0.000 description 2
• 208000009017 Athetosis Diseases 0.000 description 2
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
• 101150021723 Atp1a3 gene Proteins 0.000 description 2
• 208000032312 Autosomal recessive spastic ataxia with leukoencephalopathy Diseases 0.000 description 2
• 101150072027 BTD gene Proteins 0.000 description 2
• WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
• ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
• 206010010947 Coordination abnormal Diseases 0.000 description 2
• 102100038800 Cytochrome c oxidase assembly protein COX20, mitochondrial Human genes 0.000 description 2
• 108010009540 DNA (Cytosine-5-)-Methyltransferase 1 Proteins 0.000 description 2
• 102100036279 DNA (cytosine-5)-methyltransferase 1 Human genes 0.000 description 2
• 108090001056 DNA (cytosine-5-)-methyltransferases Proteins 0.000 description 2
• 102000004863 DNA (cytosine-5-)-methyltransferases Human genes 0.000 description 2
• 108010014080 DNA Polymerase gamma Proteins 0.000 description 2
• 102000016903 DNA Polymerase gamma Human genes 0.000 description 2
• 102220564167 DNA polymerase subunit gamma-1_E1143G_mutation Human genes 0.000 description 2
• 208000019505 Deglutition disease Diseases 0.000 description 2
• 101150007297 Dnmt1 gene Proteins 0.000 description 2
• 102000008013 Electron Transport Complex I Human genes 0.000 description 2
• 108010089760 Electron Transport Complex I Proteins 0.000 description 2
• 102100030695 Electron transfer flavoprotein subunit alpha, mitochondrial Human genes 0.000 description 2
• 241000196324 Embryophyta Species 0.000 description 2
• 108060002716 Exonuclease Proteins 0.000 description 2
• MBMLMWLHJBBADN-UHFFFAOYSA-N Ferrous sulfide Chemical compound [Fe]=S MBMLMWLHJBBADN-UHFFFAOYSA-N 0.000 description 2
• 208000001362 Fetal Growth Retardation Diseases 0.000 description 2
• PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
• 206010070531 Foetal growth restriction Diseases 0.000 description 2
• 102000003869 Frataxin Human genes 0.000 description 2
• 108090000217 Frataxin Proteins 0.000 description 2
• 201000011240 Frontotemporal dementia Diseases 0.000 description 2
• 101150103820 Fxn gene Proteins 0.000 description 2
• 102000013446 GTP Phosphohydrolases Human genes 0.000 description 2
• 108091006109 GTPases Proteins 0.000 description 2
• 206010064571 Gene mutation Diseases 0.000 description 2
• 102000053171 Glial Fibrillary Acidic Human genes 0.000 description 2
• 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 2
• 208000012766 Growth delay Diseases 0.000 description 2
• 206010053759 Growth retardation Diseases 0.000 description 2
• ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
• 101000725614 Homo sapiens 4-hydroxybenzoate polyprenyltransferase, mitochondrial Proteins 0.000 description 2
• 101000957223 Homo sapiens Cytochrome c oxidase assembly protein COX20, mitochondrial Proteins 0.000 description 2
• 101000725401 Homo sapiens Cytochrome c oxidase subunit 2 Proteins 0.000 description 2
• 101001010541 Homo sapiens Electron transfer flavoprotein subunit alpha, mitochondrial Proteins 0.000 description 2
• 101000677891 Homo sapiens Iron-sulfur clusters transporter ABCB7, mitochondrial Proteins 0.000 description 2
• 101000604411 Homo sapiens NADH-ubiquinone oxidoreductase chain 1 Proteins 0.000 description 2
• 101000722063 Homo sapiens Optic atrophy 3 protein Proteins 0.000 description 2
• 208000023105 Huntington disease Diseases 0.000 description 2
• OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
• 206010020660 Hyperlactacidaemia Diseases 0.000 description 2
• 208000005018 Hyperlactatemia Diseases 0.000 description 2
• 206010065973 Iron Overload Diseases 0.000 description 2
• 102000005298 Iron-Sulfur Proteins Human genes 0.000 description 2
• 108010081409 Iron-Sulfur Proteins Proteins 0.000 description 2
• 102100021504 Iron-sulfur clusters transporter ABCB7, mitochondrial Human genes 0.000 description 2
• 206010048804 Kearns-Sayre syndrome Diseases 0.000 description 2
• LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical group CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 2
• 206010025476 Malabsorption Diseases 0.000 description 2
• 208000004155 Malabsorption Syndromes Diseases 0.000 description 2
• 208000005767 Megalencephaly Diseases 0.000 description 2
• 208000000682 Megaloblastic Anemia Diseases 0.000 description 2
• 108010052285 Membrane Proteins Proteins 0.000 description 2
• 101710187021 Methionine-tRNA ligase, mitochondrial Proteins 0.000 description 2
• 208000019695 Migraine disease Diseases 0.000 description 2
• 102000006404 Mitochondrial Proteins Human genes 0.000 description 2
• 108010058682 Mitochondrial Proteins Proteins 0.000 description 2
• 108010006519 Molecular Chaperones Proteins 0.000 description 2
• 208000026072 Motor neurone disease Diseases 0.000 description 2
• 101150066973 Mtpap gene Proteins 0.000 description 2
• BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 2
• 102100038625 NADH-ubiquinone oxidoreductase chain 1 Human genes 0.000 description 2
• 101150025532 NUBPL gene Proteins 0.000 description 2
• 208000008457 Neurologic Manifestations Diseases 0.000 description 2
• 101150045559 Opa1 gene Proteins 0.000 description 2
• 102100025325 Optic atrophy 3 protein Human genes 0.000 description 2
• 101150078890 POLG gene Proteins 0.000 description 2
• 108091036407 Polyadenylation Proteins 0.000 description 2
• 206010036105 Polyneuropathy Diseases 0.000 description 2
• 101710083944 Probable methionine-tRNA ligase, mitochondrial Proteins 0.000 description 2
• 206010037213 Psychomotor retardation Diseases 0.000 description 2
• LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
• 208000007014 Retinitis pigmentosa Diseases 0.000 description 2
• 101150005552 SACS gene Proteins 0.000 description 2
• 208000020221 Short stature Diseases 0.000 description 2
• 101150099445 TPK1 gene Proteins 0.000 description 2
• XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
• 102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 description 2
• 108050007567 Wolframin Proteins 0.000 description 2
• 102100036022 Wolframin Human genes 0.000 description 2
• IKWTVSLWAPBBKU-UHFFFAOYSA-N a1010_sial Chemical compound O=[As]O[As]=O IKWTVSLWAPBBKU-UHFFFAOYSA-N 0.000 description 2
• 230000032683 aging Effects 0.000 description 2
• 150000001412 amines Chemical class 0.000 description 2
• 230000003078 antioxidant effect Effects 0.000 description 2
• 238000013459 approach Methods 0.000 description 2
• 229960002594 arsenic trioxide Drugs 0.000 description 2
• 125000002102 aryl alkyloxo group Chemical group 0.000 description 2
• 125000004104 aryloxy group Chemical group 0.000 description 2
• 208000013414 ataxia-telangiectasia-like disease Diseases 0.000 description 2
• 208000019531 autosomal dominant progressive external ophthalmoplegia with mitochondrial DNA deletions 2 Diseases 0.000 description 2
• 210000003050 axon Anatomy 0.000 description 2
• 239000003012 bilayer membrane Substances 0.000 description 2
• 230000033228 biological regulation Effects 0.000 description 2
• 210000000133 brain stem Anatomy 0.000 description 2
• GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
• 239000011575 calcium Substances 0.000 description 2
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
• 230000003197 catalytic effect Effects 0.000 description 2
• 230000032823 cell division Effects 0.000 description 2
• 238000006243 chemical reaction Methods 0.000 description 2
• 230000001684 chronic effect Effects 0.000 description 2
• 230000007882 cirrhosis Effects 0.000 description 2
• 230000006999 cognitive decline Effects 0.000 description 2
• 239000010949 copper Substances 0.000 description 2
• 230000001054 cortical effect Effects 0.000 description 2
• 108010023472 cytochrome C oxidase subunit II Proteins 0.000 description 2
• 229940104302 cytosine Drugs 0.000 description 2
• 230000001086 cytosolic effect Effects 0.000 description 2
• 230000001419 dependent effect Effects 0.000 description 2
• 201000010064 diabetes insipidus Diseases 0.000 description 2
• 230000037213 diet Effects 0.000 description 2
• ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 description 2
• 229960003638 dopamine Drugs 0.000 description 2
• 230000005584 early death Effects 0.000 description 2
• 210000005069 ears Anatomy 0.000 description 2
• 206010014663 endocardial fibroelastosis Diseases 0.000 description 2
• 230000037149 energy metabolism Effects 0.000 description 2
• 230000003203 everyday effect Effects 0.000 description 2
• 210000003020 exocrine pancreas Anatomy 0.000 description 2
• 102000013165 exonuclease Human genes 0.000 description 2
• 238000002474 experimental method Methods 0.000 description 2
• 208000030941 fetal growth restriction Diseases 0.000 description 2
• 210000002950 fibroblast Anatomy 0.000 description 2
• 230000004761 fibrosis Effects 0.000 description 2
• 239000011737 fluorine Substances 0.000 description 2
• 230000005021 gait Effects 0.000 description 2
• 102000054766 genetic haplotypes Human genes 0.000 description 2
• 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 2
• 231100000001 growth retardation Toxicity 0.000 description 2
• 210000002216 heart Anatomy 0.000 description 2
• 108700039582 histidine triad Proteins 0.000 description 2
• 208000006278 hypochromic anemia Diseases 0.000 description 2
• 125000002632 imidazolidinyl group Chemical group 0.000 description 2
• 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 description 2
• 230000001771 impaired effect Effects 0.000 description 2
• 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 2
• 125000001041 indolyl group Chemical group 0.000 description 2
• 230000002401 inhibitory effect Effects 0.000 description 2
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
• 230000000366 juvenile effect Effects 0.000 description 2
• 230000003902 lesion Effects 0.000 description 2
• 230000033001 locomotion Effects 0.000 description 2
• 231100000864 loss of vision Toxicity 0.000 description 2
• 208000018769 loss of vision Diseases 0.000 description 2
• 231100001016 megaloblastic anemia Toxicity 0.000 description 2
• 206010027599 migraine Diseases 0.000 description 2
• 230000004898 mitochondrial function Effects 0.000 description 2
• GVZFUVXPTPGOQT-UHFFFAOYSA-M mitoq Chemical compound CS([O-])(=O)=O.O=C1C(OC)=C(OC)C(=O)C(CCCCCCCCCC[P+](C=2C=CC=CC=2)(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1C GVZFUVXPTPGOQT-UHFFFAOYSA-M 0.000 description 2
• 230000000394 mitotic effect Effects 0.000 description 2
• 125000002950 monocyclic group Chemical group 0.000 description 2
• 125000002757 morpholinyl group Chemical group 0.000 description 2
• 208000005264 motor neuron disease Diseases 0.000 description 2
• 201000000585 muscular atrophy Diseases 0.000 description 2
• 208000012687 myopathy with extrapyramidal signs Diseases 0.000 description 2
• 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
• 229950006238 nadide Drugs 0.000 description 2
• 125000001624 naphthyl group Chemical group 0.000 description 2
• 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
• 210000002569 neuron Anatomy 0.000 description 2
• 208000004235 neutropenia Diseases 0.000 description 2
• 210000000440 neutrophil Anatomy 0.000 description 2
• 125000006574 non-aromatic ring group Chemical group 0.000 description 2
• 210000003924 normoblast Anatomy 0.000 description 2
• 235000015097 nutrients Nutrition 0.000 description 2
• 206010029864 nystagmus Diseases 0.000 description 2
• 239000003921 oil Substances 0.000 description 2
• 235000019198 oils Nutrition 0.000 description 2
• 210000000287 oocyte Anatomy 0.000 description 2
• 238000012014 optical coherence tomography Methods 0.000 description 2
• 230000010627 oxidative phosphorylation Effects 0.000 description 2
• 125000004043 oxo group Chemical group O=* 0.000 description 2
• 125000004430 oxygen atom Chemical group O* 0.000 description 2
• 210000000496 pancreas Anatomy 0.000 description 2
• 230000001717 pathogenic effect Effects 0.000 description 2
• 230000001575 pathological effect Effects 0.000 description 2
• 201000007809 peroxisome biogenesis disorder 3A Diseases 0.000 description 2
• 150000004714 phosphonium salts Chemical class 0.000 description 2
• 230000007824 polyneuropathy Effects 0.000 description 2
• 102000040430 polynucleotide Human genes 0.000 description 2
• 108091033319 polynucleotide Proteins 0.000 description 2
• 239000002157 polynucleotide Substances 0.000 description 2
• 208000004351 pontocerebellar hypoplasia Diseases 0.000 description 2
• 230000035935 pregnancy Effects 0.000 description 2
• 208000037821 progressive disease Diseases 0.000 description 2
• 230000000069 prophylactic effect Effects 0.000 description 2
• 238000007634 remodeling Methods 0.000 description 2
• 230000008439 repair process Effects 0.000 description 2
• 230000010076 replication Effects 0.000 description 2
• 230000027756 respiratory electron transport chain Effects 0.000 description 2
• 102200121724 rs80356529 Human genes 0.000 description 2
• 206010039722 scoliosis Diseases 0.000 description 2
• 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
• 238000005204 segregation Methods 0.000 description 2
• 229940076279 serotonin Drugs 0.000 description 2
• 230000001568 sexual effect Effects 0.000 description 2
• 229910001415 sodium ion Inorganic materials 0.000 description 2
• 239000000758 substrate Substances 0.000 description 2
• 238000003786 synthesis reaction Methods 0.000 description 2
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
• 229960002363 thiamine pyrophosphate Drugs 0.000 description 2
• 235000008170 thiamine pyrophosphate Nutrition 0.000 description 2
• 239000011678 thiamine pyrophosphate Substances 0.000 description 2
• YXVCLPJQTZXJLH-UHFFFAOYSA-N thiamine(1+) diphosphate chloride Chemical compound [Cl-].CC1=C(CCOP(O)(=O)OP(O)(O)=O)SC=[N+]1CC1=CN=C(C)N=C1N YXVCLPJQTZXJLH-UHFFFAOYSA-N 0.000 description 2
• SQQWBSBBCSFQGC-JLHYYAGUSA-N ubiquinone-2 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CCC=C(C)C)=C(C)C1=O SQQWBSBBCSFQGC-JLHYYAGUSA-N 0.000 description 2
• 230000002485 urinary effect Effects 0.000 description 2
• 210000001635 urinary tract Anatomy 0.000 description 2
• 230000004304 visual acuity Effects 0.000 description 2
• 208000030402 vitamin D-dependent rickets Diseases 0.000 description 2
• 230000003442 weekly effect Effects 0.000 description 2
• SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
• 125000006727 (C1-C6) alkenyl group Chemical group 0.000 description 1
• 229930182837 (R)-adrenaline Natural products 0.000 description 1
• UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
• 125000001560 (R)-dihydrolipoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[C@](S[H])([H])C([H])([H])C([H])([H])S[H] 0.000 description 1
• UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
• YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
• KPGXRSRHYNQIFN-UHFFFAOYSA-L 2-oxoglutarate(2-) Chemical compound [O-]C(=O)CCC(=O)C([O-])=O KPGXRSRHYNQIFN-UHFFFAOYSA-L 0.000 description 1
• BSENIZCJJAZGSB-UHFFFAOYSA-N 3-hydroxy-3-[(trimethylazaniumyl)methyl]tridecanoate Chemical compound C(CCCCCCCCC)C(O)(C[N+](C)(C)C)CC([O-])=O BSENIZCJJAZGSB-UHFFFAOYSA-N 0.000 description 1
• 201000003553 3-methylglutaconic aciduria Diseases 0.000 description 1
• FJKROLUGYXJWQN-UHFFFAOYSA-M 4-hydroxybenzoate Chemical compound OC1=CC=C(C([O-])=O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-M 0.000 description 1
• AHASLLQCJNEMQG-UHFFFAOYSA-N 5-methyl-1h-pyrimidine-2,4-dione;phosphono dihydrogen phosphate Chemical compound CC1=CNC(=O)NC1=O.OP(O)(=O)OP(O)(O)=O AHASLLQCJNEMQG-UHFFFAOYSA-N 0.000 description 1
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
• 101150036609 ARMS2 gene Proteins 0.000 description 1
• 108010071550 ATP-Dependent Proteases Proteins 0.000 description 1
• 102000007566 ATP-Dependent Proteases Human genes 0.000 description 1
• 108091006112 ATPases Proteins 0.000 description 1
• 101150072286 ATXN7 gene Proteins 0.000 description 1
• 206010000234 Abortion spontaneous Diseases 0.000 description 1
• 101150040074 Aco2 gene Proteins 0.000 description 1
• 102100040958 Aconitate hydratase, mitochondrial Human genes 0.000 description 1
• 102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
• 102100038568 Age-related maculopathy susceptibility protein 2 Human genes 0.000 description 1
• 206010001541 Akinesia Diseases 0.000 description 1
• 108700042932 Alpha-ketoglutarate dehydrogenase deficiency Proteins 0.000 description 1
• 208000024985 Alport syndrome Diseases 0.000 description 1
• 206010002064 Anaemia macrocytic Diseases 0.000 description 1
• 208000032467 Aplastic anaemia Diseases 0.000 description 1
• 108010033604 Apoptosis Inducing Factor Proteins 0.000 description 1
• 102000007272 Apoptosis Inducing Factor Human genes 0.000 description 1
• 206010003062 Apraxia Diseases 0.000 description 1
• 206010003571 Astrocytoma Diseases 0.000 description 1
• 208000012219 Autonomic Nervous System disease Diseases 0.000 description 1
• 241000133570 Berberidaceae Species 0.000 description 1
• 206010004906 Biotin deficiency Diseases 0.000 description 1
• 208000002381 Brain Hypoxia Diseases 0.000 description 1
• KSFOVUSSGSKXFI-GAQDCDSVSA-N CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O Chemical compound CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O KSFOVUSSGSKXFI-GAQDCDSVSA-N 0.000 description 1
• 101150052306 CHCHD10 gene Proteins 0.000 description 1
• 101150071146 COX2 gene Proteins 0.000 description 1
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
• 101100507655 Canis lupus familiaris HSPA1 gene Proteins 0.000 description 1
• 208000002061 Cardiac Conduction System Disease Diseases 0.000 description 1
• 108010078791 Carrier Proteins Proteins 0.000 description 1
• 208000001573 Cataplexy Diseases 0.000 description 1
• 208000022852 Cerebellar ataxia-areflexia-pes cavus-optic atrophy-sensorineural hearing loss syndrome Diseases 0.000 description 1
• 206010008072 Cerebellar syndrome Diseases 0.000 description 1
• 206010008635 Cholestasis Diseases 0.000 description 1
• 206010008754 Choreoathetosis Diseases 0.000 description 1
• 208000033825 Chorioretinal atrophy Diseases 0.000 description 1
• 108010077544 Chromatin Proteins 0.000 description 1
• 208000017667 Chronic Disease Diseases 0.000 description 1
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
• 206010009346 Clonus Diseases 0.000 description 1
• 102100023677 Coiled-coil-helix-coiled-coil-helix domain-containing protein 10, mitochondrial Human genes 0.000 description 1
• 208000006992 Color Vision Defects Diseases 0.000 description 1
• 208000036693 Color-vision disease Diseases 0.000 description 1
• 208000002330 Congenital Heart Defects Diseases 0.000 description 1
• 206010010356 Congenital anomaly Diseases 0.000 description 1
• 241000689227 Cora <basidiomycete fungus> Species 0.000 description 1
• 101150022431 Cox20 gene Proteins 0.000 description 1
• 102100030497 Cytochrome c Human genes 0.000 description 1
• 102100030878 Cytochrome c oxidase subunit 1 Human genes 0.000 description 1
• 102100027456 Cytochrome c oxidase subunit 2 Human genes 0.000 description 1
• 102000015884 Cytochrome c oxidase subunit I Human genes 0.000 description 1
• 108050004212 Cytochrome c oxidase subunit I Proteins 0.000 description 1
• 108010075031 Cytochromes c Proteins 0.000 description 1
• 101150013950 DLD gene Proteins 0.000 description 1
• 102100036951 DNA polymerase subunit gamma-1 Human genes 0.000 description 1
• 102000039171 DNA polymerase type-B-like family Human genes 0.000 description 1
• 108091066220 DNA polymerase type-B-like family Proteins 0.000 description 1
• 230000033616 DNA repair Effects 0.000 description 1
• 230000004543 DNA replication Effects 0.000 description 1
• 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
• 101710096438 DNA-binding protein Proteins 0.000 description 1
• 206010011882 Deafness congenital Diseases 0.000 description 1
• 206010067502 Decreased vibratory sense Diseases 0.000 description 1
• 206010012205 Delayed puberty Diseases 0.000 description 1
• 208000016192 Demyelinating disease Diseases 0.000 description 1
• 206010012305 Demyelination Diseases 0.000 description 1
• 206010012735 Diarrhoea Diseases 0.000 description 1
• 102100031920 Dihydrolipoyllysine-residue succinyltransferase component of 2-oxoglutarate dehydrogenase complex, mitochondrial Human genes 0.000 description 1
• 101100186820 Drosophila melanogaster sicily gene Proteins 0.000 description 1
• 208000001654 Drug Resistant Epilepsy Diseases 0.000 description 1
• 108091006149 Electron carriers Proteins 0.000 description 1
• 241001658031 Eris Species 0.000 description 1
• 208000019749 Eye movement disease Diseases 0.000 description 1
• 101150062740 FARS2 gene Proteins 0.000 description 1
• 206010051267 Facial paresis Diseases 0.000 description 1
• 102220559922 Fibrillin-1_C596R_mutation Human genes 0.000 description 1
• 206010055690 Foetal death Diseases 0.000 description 1
• 206010018341 Gliosis Diseases 0.000 description 1
• 108010015899 Glycopeptides Proteins 0.000 description 1
• 102000002068 Glycopeptides Human genes 0.000 description 1
• 102000003886 Glycoproteins Human genes 0.000 description 1
• 108090000288 Glycoproteins Proteins 0.000 description 1
• 208000034596 Gyrate atrophy of choroid and retina Diseases 0.000 description 1
• 102000018932 HSP70 Heat-Shock Proteins Human genes 0.000 description 1
• 108010027992 HSP70 Heat-Shock Proteins Proteins 0.000 description 1
• 208000031856 Haemosiderosis Diseases 0.000 description 1
• 206010019280 Heart failures Diseases 0.000 description 1
• 208000032843 Hemorrhage Diseases 0.000 description 1
• 208000017987 Hereditary myopathy with lactic acidosis due to ISCU deficiency Diseases 0.000 description 1
• 108010033040 Histones Proteins 0.000 description 1
• 208000027768 Hoffmann sign Diseases 0.000 description 1
• 241000282412 Homo Species 0.000 description 1
• 101100164990 Homo sapiens ATXN7 gene Proteins 0.000 description 1
• 101000965314 Homo sapiens Aconitate hydratase, mitochondrial Proteins 0.000 description 1
• 101000808726 Homo sapiens Age-related maculopathy susceptibility protein 2 Proteins 0.000 description 1
• 101000757586 Homo sapiens Aprataxin Proteins 0.000 description 1
• 101000630206 Homo sapiens Aspartate-tRNA ligase, mitochondrial Proteins 0.000 description 1
• 101000907013 Homo sapiens Coiled-coil-helix-coiled-coil-helix domain-containing protein 10, mitochondrial Proteins 0.000 description 1
• 101000919849 Homo sapiens Cytochrome c oxidase subunit 1 Proteins 0.000 description 1
• 101000804964 Homo sapiens DNA polymerase subunit gamma-1 Proteins 0.000 description 1
• 101000992065 Homo sapiens Dihydrolipoyllysine-residue succinyltransferase component of 2-oxoglutarate dehydrogenase complex, mitochondrial Proteins 0.000 description 1
• 101100229399 Homo sapiens GLRX5 gene Proteins 0.000 description 1
• 101000787809 Homo sapiens Methionine-tRNA ligase, mitochondrial Proteins 0.000 description 1
• 101000697649 Homo sapiens Mitochondrial chaperone BCS1 Proteins 0.000 description 1
• 101000595929 Homo sapiens POLG alternative reading frame Proteins 0.000 description 1
• 101000605122 Homo sapiens Prostaglandin G/H synthase 1 Proteins 0.000 description 1
• 101000688672 Homo sapiens Sideroflexin-4 Proteins 0.000 description 1
• 101100264019 Homo sapiens WFS1 gene Proteins 0.000 description 1
• 208000006031 Hydrops Fetalis Diseases 0.000 description 1
• PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
• 208000035150 Hypercholesterolemia Diseases 0.000 description 1
• 208000008454 Hyperhidrosis Diseases 0.000 description 1
• 206010048865 Hypoacusis Diseases 0.000 description 1
• 206010070511 Hypoxic-ischaemic encephalopathy Diseases 0.000 description 1
• 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• 206010021518 Impaired gastric emptying Diseases 0.000 description 1
• 206010021567 Impulsive behaviour Diseases 0.000 description 1
• 208000026350 Inborn Genetic disease Diseases 0.000 description 1
• 206010021639 Incontinence Diseases 0.000 description 1
• 206010061218 Inflammation Diseases 0.000 description 1
• 201000006347 Intellectual Disability Diseases 0.000 description 1
• 108010044467 Isoenzymes Proteins 0.000 description 1
• 206010023126 Jaundice Diseases 0.000 description 1
• UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical group OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical group CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
• QEFRNWWLZKMPFJ-ZXPFJRLXSA-N L-methionine (R)-S-oxide Chemical group C[S@@](=O)CC[C@H]([NH3+])C([O-])=O QEFRNWWLZKMPFJ-ZXPFJRLXSA-N 0.000 description 1
• QEFRNWWLZKMPFJ-UHFFFAOYSA-N L-methionine sulphoxide Chemical group CS(=O)CCC(N)C(O)=O QEFRNWWLZKMPFJ-UHFFFAOYSA-N 0.000 description 1
• 208000030979 Language Development disease Diseases 0.000 description 1
• 206010024264 Lethargy Diseases 0.000 description 1
• 208000035752 Live birth Diseases 0.000 description 1
• 101150051213 MAOA gene Proteins 0.000 description 1
• 206010050183 Macrocephaly Diseases 0.000 description 1
• 208000035719 Maculopathy Diseases 0.000 description 1
• 241000124008 Mammalia Species 0.000 description 1
• 101710159527 Maturation protein A Proteins 0.000 description 1
• 101710091157 Maturation protein A2 Proteins 0.000 description 1
• 102100025912 Melanopsin Human genes 0.000 description 1
• 102000018697 Membrane Proteins Human genes 0.000 description 1
• ABSPRNADVQNDOU-UHFFFAOYSA-N Menaquinone 1 Natural products C1=CC=C2C(=O)C(CC=C(C)C)=C(C)C(=O)C2=C1 ABSPRNADVQNDOU-UHFFFAOYSA-N 0.000 description 1
• 206010061285 Mental disorder due to a general medical condition Diseases 0.000 description 1
• 206010027374 Mental impairment Diseases 0.000 description 1
• 206010027417 Metabolic acidosis Diseases 0.000 description 1
• 102000000362 Methionyl-tRNA synthetases Human genes 0.000 description 1
• 108050008914 Methionyl-tRNA synthetases Proteins 0.000 description 1
• 206010027540 Microcytosis Diseases 0.000 description 1
• 206010027566 Micturition urgency Diseases 0.000 description 1
• 208000036769 Mild mental retardation Diseases 0.000 description 1
• 102000000298 Mrp/NBP35 ATP-binding proteins Human genes 0.000 description 1
• 108050008768 Mrp/NBP35 ATP-binding proteins Proteins 0.000 description 1
• 102000002568 Multienzyme Complexes Human genes 0.000 description 1
• 108010093369 Multienzyme Complexes Proteins 0.000 description 1
• 208000001089 Multiple system atrophy Diseases 0.000 description 1
• 208000002740 Muscle Rigidity Diseases 0.000 description 1
• 206010052904 Musculoskeletal stiffness Diseases 0.000 description 1
• 108010021466 Mutant Proteins Proteins 0.000 description 1
• 102000008300 Mutant Proteins Human genes 0.000 description 1
• CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
• 108010086428 NADH Dehydrogenase Proteins 0.000 description 1
• 102000006746 NADH Dehydrogenase Human genes 0.000 description 1
• 102000034570 NR1 subfamily Human genes 0.000 description 1
• 108020001305 NR1 subfamily Proteins 0.000 description 1
• 206010028851 Necrosis Diseases 0.000 description 1
• 208000020241 Neonatal disease Diseases 0.000 description 1
• 208000012902 Nervous system disease Diseases 0.000 description 1
• 208000037129 Newborn Diseases Infant Diseases 0.000 description 1
• 208000001140 Night Blindness Diseases 0.000 description 1
• 108020004485 Nonsense Codon Proteins 0.000 description 1
• 101150010952 OAT gene Proteins 0.000 description 1
• 208000008589 Obesity Diseases 0.000 description 1
• 206010030113 Oedema Diseases 0.000 description 1
• 241000207836 Olea <angiosperm> Species 0.000 description 1
• 208000001184 Oligohydramnios Diseases 0.000 description 1
• 208000007117 Oral Ulcer Diseases 0.000 description 1
• 208000033716 Organic aciduria Diseases 0.000 description 1
• 102000004132 Ornithine aminotransferases Human genes 0.000 description 1
• 108090000691 Ornithine aminotransferases Proteins 0.000 description 1
• 206010031127 Orthostatic hypotension Diseases 0.000 description 1
• 206010033799 Paralysis Diseases 0.000 description 1
• 206010033892 Paraplegia Diseases 0.000 description 1
• 208000008469 Peptic Ulcer Diseases 0.000 description 1
• 206010034620 Peripheral sensory neuropathy Diseases 0.000 description 1
• BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical compound NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 description 1
• 241000097929 Porphyria Species 0.000 description 1
• 208000010642 Porphyrias Diseases 0.000 description 1
• 108010001267 Protein Subunits Proteins 0.000 description 1
• 102000002067 Protein Subunits Human genes 0.000 description 1
• 208000028017 Psychotic disease Diseases 0.000 description 1
• 206010037660 Pyrexia Diseases 0.000 description 1
• 101150053429 RNA14 gene Proteins 0.000 description 1
• 101150111235 RRM2B gene Proteins 0.000 description 1
• 208000001647 Renal Insufficiency Diseases 0.000 description 1
• 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
• 201000007737 Retinal degeneration Diseases 0.000 description 1
• 208000017442 Retinal disease Diseases 0.000 description 1
• 206010038923 Retinopathy Diseases 0.000 description 1
• 108091006780 SLC19A2 Proteins 0.000 description 1
• 101150003672 SLC25A38 gene Proteins 0.000 description 1
• 101100060989 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) COQ8 gene Proteins 0.000 description 1
• 206010040047 Sepsis Diseases 0.000 description 1
• 102100024223 Sideroflexin-4 Human genes 0.000 description 1
• FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
• 208000032930 Spastic paraplegia Diseases 0.000 description 1
• 208000010112 Spinocerebellar Degenerations Diseases 0.000 description 1
• 208000032005 Spinocerebellar ataxia with axonal neuropathy type 2 Diseases 0.000 description 1
• 206010041969 Steatorrhoea Diseases 0.000 description 1
• 101000895926 Streptomyces plicatus Endo-beta-N-acetylglucosaminidase H Proteins 0.000 description 1
• 208000010513 Stupor Diseases 0.000 description 1
• 206010049418 Sudden Cardiac Death Diseases 0.000 description 1
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
• UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
• 101150025256 TAZ gene Proteins 0.000 description 1
• 101710175789 Tafazzin Proteins 0.000 description 1
• 101710128787 Thiamine transporter Proteins 0.000 description 1
• 102000040945 Transcription factor Human genes 0.000 description 1
• 108091023040 Transcription factor Proteins 0.000 description 1
• 102000014701 Transketolase Human genes 0.000 description 1
• 108010043652 Transketolase Proteins 0.000 description 1
• 241000219793 Trifolium Species 0.000 description 1
• 208000031861 Tritanopia Diseases 0.000 description 1
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
• 206010047281 Ventricular arrhythmia Diseases 0.000 description 1
• 229930003270 Vitamin B Natural products 0.000 description 1
• 229930003756 Vitamin B7 Natural products 0.000 description 1
• 206010047642 Vitiligo Diseases 0.000 description 1
• 206010047700 Vomiting Diseases 0.000 description 1
• 206010072731 White matter lesion Diseases 0.000 description 1
• 210000001766 X chromosome Anatomy 0.000 description 1
• 208000022440 X-linked sideroblastic anemia 1 Diseases 0.000 description 1
• 101710185494 Zinc finger protein Proteins 0.000 description 1
• 102100023597 Zinc finger protein 816 Human genes 0.000 description 1
• 230000001594 aberrant effect Effects 0.000 description 1
• 230000004598 abnormal eye movement Effects 0.000 description 1
• 125000004423 acyloxy group Chemical group 0.000 description 1
• 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
• 239000000654 additive Substances 0.000 description 1
• 125000005426 adeninyl group Chemical group N1=C(N=C2N=CNC2=C1N)* 0.000 description 1
• 230000002776 aggregation Effects 0.000 description 1
• 238000004220 aggregation Methods 0.000 description 1
• 208000012761 aggressive behavior Diseases 0.000 description 1
• 229930013930 alkaloid Natural products 0.000 description 1
• 150000003797 alkaloid derivatives Chemical class 0.000 description 1
• 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
• 125000000278 alkyl amino alkyl group Chemical group 0.000 description 1
• 125000005037 alkyl phenyl group Chemical group 0.000 description 1
• 125000004656 alkyl sulfonylamino group Chemical group 0.000 description 1
• 125000004414 alkyl thio group Chemical group 0.000 description 1
• 210000000975 allocortex Anatomy 0.000 description 1
• 230000001668 ameliorated effect Effects 0.000 description 1
• 150000001409 amidines Chemical class 0.000 description 1
• 230000006229 amino acid addition Effects 0.000 description 1
• 125000003277 amino group Chemical group 0.000 description 1
• 125000004103 aminoalkyl group Chemical group 0.000 description 1
• 229960002749 aminolevulinic acid Drugs 0.000 description 1
• 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 1
• 229910021529 ammonia Inorganic materials 0.000 description 1
• 238000004458 analytical method Methods 0.000 description 1
• 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
• 239000003963 antioxidant agent Substances 0.000 description 1
• 235000006708 antioxidants Nutrition 0.000 description 1
• 101150036464 aptx gene Proteins 0.000 description 1
• 150000001491 aromatic compounds Chemical class 0.000 description 1
• 210000001130 astrocyte Anatomy 0.000 description 1
• 230000003140 astrocytic effect Effects 0.000 description 1
• 201000008713 ataxia with oculomotor apraxia type 1 Diseases 0.000 description 1
• 208000031565 ataxia, early-onset, with oculomotor apraxia and hypoalbuminemia Diseases 0.000 description 1
• 230000001977 ataxic effect Effects 0.000 description 1
• 125000004429 atom Chemical group 0.000 description 1
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
• 210000003984 auditory pathway Anatomy 0.000 description 1
• 208000028281 autosomal inheritance Diseases 0.000 description 1
• 208000033361 autosomal recessive with axonal neuropathy 2 spinocerebellar ataxia Diseases 0.000 description 1
• 230000003376 axonal effect Effects 0.000 description 1
• 125000005602 azabenzimidazolyl group Chemical group 0.000 description 1
• 125000005334 azaindolyl group Chemical group N1N=C(C2=CC=CC=C12)* 0.000 description 1
• 125000002393 azetidinyl group Chemical group 0.000 description 1
• 125000004069 aziridinyl group Chemical group 0.000 description 1
• 125000003828 azulenyl group Chemical group 0.000 description 1
• 201000005008 bacterial sepsis Diseases 0.000 description 1
• 230000033590 base-excision repair Effects 0.000 description 1
• 238000009412 basement excavation Methods 0.000 description 1
• 230000003542 behavioural effect Effects 0.000 description 1
• 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
• 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
• 125000005874 benzothiadiazolyl group Chemical group 0.000 description 1
• 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
• 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
• 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
• 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
• 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
• 125000002619 bicyclic group Chemical group 0.000 description 1
• JSMRMEYFZHIPJV-UHFFFAOYSA-N bicyclo[2.1.1]hexane Chemical compound C1C2CC1CC2 JSMRMEYFZHIPJV-UHFFFAOYSA-N 0.000 description 1
• 210000000013 bile duct Anatomy 0.000 description 1
• 230000002715 bioenergetic effect Effects 0.000 description 1
• 230000008436 biogenesis Effects 0.000 description 1
• 230000031018 biological processes and functions Effects 0.000 description 1
• 238000001574 biopsy Methods 0.000 description 1
• 230000000740 bleeding effect Effects 0.000 description 1
• 210000004204 blood vessel Anatomy 0.000 description 1
• 201000010018 blue color blindness Diseases 0.000 description 1
• 230000036760 body temperature Effects 0.000 description 1
• 230000037396 body weight Effects 0.000 description 1
• 210000004899 c-terminal region Anatomy 0.000 description 1
• 229910052791 calcium Inorganic materials 0.000 description 1
• 201000011510 cancer Diseases 0.000 description 1
• 239000004202 carbamide Substances 0.000 description 1
• 125000001589 carboacyl group Chemical group 0.000 description 1
• 150000001720 carbohydrates Chemical class 0.000 description 1
• 235000014633 carbohydrates Nutrition 0.000 description 1
• 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
• 125000004181 carboxyalkyl group Chemical group 0.000 description 1
• 229960004203 carnitine Drugs 0.000 description 1
• 239000000969 carrier Substances 0.000 description 1
• 230000015556 catabolic process Effects 0.000 description 1
• 125000002091 cationic group Chemical group 0.000 description 1
• 230000005779 cell damage Effects 0.000 description 1
• 230000030833 cell death Effects 0.000 description 1
• 208000037887 cell injury Diseases 0.000 description 1
• 210000000170 cell membrane Anatomy 0.000 description 1
• 230000001413 cellular effect Effects 0.000 description 1
• 230000033077 cellular process Effects 0.000 description 1
• 230000036755 cellular response Effects 0.000 description 1
• 210000003169 central nervous system Anatomy 0.000 description 1
• 208000025434 cerebellar degeneration Diseases 0.000 description 1
• 201000004559 cerebral degeneration Diseases 0.000 description 1
• 238000007385 chemical modification Methods 0.000 description 1
• 208000011654 childhood malignant neoplasm Diseases 0.000 description 1
• 125000000068 chlorophenyl group Chemical group 0.000 description 1
• 230000007870 cholestasis Effects 0.000 description 1
• 231100000359 cholestasis Toxicity 0.000 description 1
• 210000003483 chromatin Anatomy 0.000 description 1
• 230000027288 circadian rhythm Effects 0.000 description 1
• GTZCVFVGUGFEME-IWQZZHSRSA-N cis-aconitic acid Chemical compound OC(=O)C\C(C(O)=O)=C\C(O)=O GTZCVFVGUGFEME-IWQZZHSRSA-N 0.000 description 1
• 208000035850 clinical syndrome Diseases 0.000 description 1
• 210000000860 cochlear nerve Anatomy 0.000 description 1
• 229940110767 coenzyme Q10 Drugs 0.000 description 1
• 230000007278 cognition impairment Effects 0.000 description 1
• 230000004456 color vision Effects 0.000 description 1
• 208000028831 congenital heart disease Diseases 0.000 description 1
• 101150008009 coq-2 gene Proteins 0.000 description 1
• 239000013078 crystal Substances 0.000 description 1
• 125000004093 cyano group Chemical group *C#N 0.000 description 1
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
• 210000000805 cytoplasm Anatomy 0.000 description 1
• 125000003493 decenyl group Chemical group [H]C([*])=C([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 125000005070 decynyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C#C* 0.000 description 1
• 230000005786 degenerative changes Effects 0.000 description 1
• 238000006731 degradation reaction Methods 0.000 description 1
• 230000001934 delay Effects 0.000 description 1
• 230000002939 deleterious effect Effects 0.000 description 1
• 230000002638 denervation Effects 0.000 description 1
• 230000000994 depressogenic effect Effects 0.000 description 1
• 230000009504 deubiquitination Effects 0.000 description 1
• 230000009547 development abnormality Effects 0.000 description 1
• 229950006137 dexfosfoserine Drugs 0.000 description 1
• NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 1
• 108010028566 diadenosine polyphosphate hydrolase Proteins 0.000 description 1
• 125000004985 dialkyl amino alkyl group Chemical group 0.000 description 1
• 230000000378 dietary effect Effects 0.000 description 1
• 238000009792 diffusion process Methods 0.000 description 1
• 230000029087 digestion Effects 0.000 description 1
• SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
• PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
• 230000019975 dosage compensation by inactivation of X chromosome Effects 0.000 description 1
• 230000009977 dual effect Effects 0.000 description 1
• 150000002081 enamines Chemical class 0.000 description 1
• 230000007613 environmental effect Effects 0.000 description 1
• 230000002327 eosinophilic effect Effects 0.000 description 1
• 229960005139 epinephrine Drugs 0.000 description 1
• 210000003743 erythrocyte Anatomy 0.000 description 1
• 230000000925 erythroid effect Effects 0.000 description 1
• 150000002148 esters Chemical class 0.000 description 1
• 210000003527 eukaryotic cell Anatomy 0.000 description 1
• 238000011156 evaluation Methods 0.000 description 1
• 210000003414 extremity Anatomy 0.000 description 1
• 238000001125 extrusion Methods 0.000 description 1
• 210000000744 eyelid Anatomy 0.000 description 1
• 230000001815 facial effect Effects 0.000 description 1
• 208000010770 facial weakness Diseases 0.000 description 1
• 239000003925 fat Substances 0.000 description 1
• 208000020519 fatal multiple mitochondrial dysfunctions syndrome Diseases 0.000 description 1
• 235000019197 fats Nutrition 0.000 description 1
• 230000004720 fertilization Effects 0.000 description 1
• 230000004992 fission Effects 0.000 description 1
• 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
• 230000037406 food intake Effects 0.000 description 1
• 235000012631 food intake Nutrition 0.000 description 1
• 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
• 239000012634 fragment Substances 0.000 description 1
• 238000013467 fragmentation Methods 0.000 description 1
• 238000006062 fragmentation reaction Methods 0.000 description 1
• 230000037433 frameshift Effects 0.000 description 1
• 208000025565 frontotemporal dementia and/or amyotrophic lateral sclerosis Diseases 0.000 description 1
• 125000002541 furyl group Chemical group 0.000 description 1
• 230000004927 fusion Effects 0.000 description 1
• 208000001288 gastroparesis Diseases 0.000 description 1
• 208000016361 genetic disease Diseases 0.000 description 1
• 230000007387 gliosis Effects 0.000 description 1
• 230000034659 glycolysis Effects 0.000 description 1
• 210000004884 grey matter Anatomy 0.000 description 1
• 208000035474 group of disease Diseases 0.000 description 1
• 230000009554 growth spurt Effects 0.000 description 1
• 150000003278 haem Chemical class 0.000 description 1
• 210000002768 hair cell Anatomy 0.000 description 1
• 125000001188 haloalkyl group Chemical group 0.000 description 1
• 230000036541 health Effects 0.000 description 1
• 230000002489 hematologic effect Effects 0.000 description 1
• 206010019847 hepatosplenomegaly Diseases 0.000 description 1
• 125000002192 heptalenyl group Chemical group 0.000 description 1
• 208000003215 hereditary nephritis Diseases 0.000 description 1
• 125000006038 hexenyl group Chemical group 0.000 description 1
• 125000005980 hexynyl group Chemical group 0.000 description 1
• 238000004128 high performance liquid chromatography Methods 0.000 description 1
• 210000001320 hippocampus Anatomy 0.000 description 1
• 230000006195 histone acetylation Effects 0.000 description 1
• 150000007857 hydrazones Chemical class 0.000 description 1
• 208000003906 hydrocephalus Diseases 0.000 description 1
• 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
• 230000007062 hydrolysis Effects 0.000 description 1
• 238000006460 hydrolysis reaction Methods 0.000 description 1
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
• 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
• 229960002591 hydroxyproline Drugs 0.000 description 1
• 208000009300 hypochromic microcytic anemia Diseases 0.000 description 1
• 238000003384 imaging method Methods 0.000 description 1
• 125000002636 imidazolinyl group Chemical group 0.000 description 1
• 150000003949 imides Chemical class 0.000 description 1
• 150000002466 imines Chemical class 0.000 description 1
• 230000002779 inactivation Effects 0.000 description 1
• 208000016290 incoordination Diseases 0.000 description 1
• 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
• 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
• 210000003552 inferior colliculi Anatomy 0.000 description 1
• 230000004054 inflammatory process Effects 0.000 description 1
• 208000036971 interstitial lung disease 2 Diseases 0.000 description 1
• 238000011835 investigation Methods 0.000 description 1
• 239000011630 iodine Substances 0.000 description 1
• 229910052740 iodine Inorganic materials 0.000 description 1
• 230000010438 iron metabolism Effects 0.000 description 1
• ODBLHEXUDAPZAU-UHFFFAOYSA-N isocitric acid Chemical compound OC(=O)C(O)C(C(O)=O)CC(O)=O ODBLHEXUDAPZAU-UHFFFAOYSA-N 0.000 description 1
• 238000006317 isomerization reaction Methods 0.000 description 1
• 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• 125000000654 isopropylidene group Chemical group C(C)(C)=* 0.000 description 1
• 229930013397 isoquinoline alkaloid Natural products 0.000 description 1
• 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
• 125000000842 isoxazolyl group Chemical group 0.000 description 1
• 210000003734 kidney Anatomy 0.000 description 1
• 201000006370 kidney failure Diseases 0.000 description 1
• 208000028756 lack of coordination Diseases 0.000 description 1
• 231100000518 lethal Toxicity 0.000 description 1
• 230000001665 lethal effect Effects 0.000 description 1
• 210000000265 leukocyte Anatomy 0.000 description 1
• 150000002632 lipids Chemical class 0.000 description 1
• 230000005976 liver dysfunction Effects 0.000 description 1
• 208000018773 low birth weight Diseases 0.000 description 1
• 231100000533 low birth weight Toxicity 0.000 description 1
• 210000003141 lower extremity Anatomy 0.000 description 1
• 108010014025 m-AAA proteases Proteins 0.000 description 1
• 201000006437 macrocytic anemia Diseases 0.000 description 1
• 210000002540 macrophage Anatomy 0.000 description 1
• 238000002595 magnetic resonance imaging Methods 0.000 description 1
• 230000014759 maintenance of location Effects 0.000 description 1
• 230000010311 mammalian development Effects 0.000 description 1
• 208000003531 maternally-inherited Leigh syndrome Diseases 0.000 description 1
• 239000011159 matrix material Substances 0.000 description 1
• 230000035800 maturation Effects 0.000 description 1
• 108010005417 melanopsin Proteins 0.000 description 1
• 230000006996 mental state Effects 0.000 description 1
• 230000002503 metabolic effect Effects 0.000 description 1
• 230000037353 metabolic pathway Effects 0.000 description 1
• 230000037323 metabolic rate Effects 0.000 description 1
• 229930182817 methionine Chemical group 0.000 description 1
• LSDPWZHWYPCBBB-UHFFFAOYSA-O methylsulfide anion Chemical compound [SH2+]C LSDPWZHWYPCBBB-UHFFFAOYSA-O 0.000 description 1
• 206010062198 microangiopathy Diseases 0.000 description 1
• 208000004141 microcephaly Diseases 0.000 description 1
• 208000015994 miscarriage Diseases 0.000 description 1
• 201000002697 mitochondrial DNA depletion syndrome Diseases 0.000 description 1
• 230000006677 mitochondrial metabolism Effects 0.000 description 1
• 108091005601 modified peptides Proteins 0.000 description 1
• 230000000877 morphologic effect Effects 0.000 description 1
• 230000004899 motility Effects 0.000 description 1
• 201000002712 multiple mitochondrial dysfunctions syndrome Diseases 0.000 description 1
• 201000006417 multiple sclerosis Diseases 0.000 description 1
• 210000004165 myocardium Anatomy 0.000 description 1
• 210000000107 myocyte Anatomy 0.000 description 1
• 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 230000017074 necrotic cell death Effects 0.000 description 1
• 208000013435 necrotic lesion Diseases 0.000 description 1
• 239000013642 negative control Substances 0.000 description 1
• 210000004126 nerve fiber Anatomy 0.000 description 1
• 230000001272 neurogenic effect Effects 0.000 description 1
• 210000004498 neuroglial cell Anatomy 0.000 description 1
• 238000002610 neuroimaging Methods 0.000 description 1
• 230000009251 neurologic dysfunction Effects 0.000 description 1
• 230000007121 neuropathological change Effects 0.000 description 1
• 239000002858 neurotransmitter agent Substances 0.000 description 1
• 150000002825 nitriles Chemical class 0.000 description 1
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
• 230000037434 nonsense mutation Effects 0.000 description 1
• 229960002748 norepinephrine Drugs 0.000 description 1
• SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
• 102000006255 nuclear receptors Human genes 0.000 description 1
• 108020004017 nuclear receptors Proteins 0.000 description 1
• 235000020824 obesity Nutrition 0.000 description 1
• 208000028780 ocular motility disease Diseases 0.000 description 1
• 210000001010 olfactory tubercle Anatomy 0.000 description 1
• 208000009689 optic atrophy 4 Diseases 0.000 description 1
• 208000006042 optic atrophy 5 Diseases 0.000 description 1
• 208000012242 optic atrophy 8 Diseases 0.000 description 1
• 210000003733 optic disk Anatomy 0.000 description 1
• 208000008511 optic nerve glioma Diseases 0.000 description 1
• 210000004789 organ system Anatomy 0.000 description 1
• 210000003463 organelle Anatomy 0.000 description 1
• 201000008152 organic acidemia Diseases 0.000 description 1
• 230000001151 other effect Effects 0.000 description 1
• 230000002018 overexpression Effects 0.000 description 1
• 125000002971 oxazolyl group Chemical group 0.000 description 1
• 230000036542 oxidative stress Effects 0.000 description 1
• 239000001301 oxygen Substances 0.000 description 1
• 230000005994 pancreas dysfunction Effects 0.000 description 1
• 230000003071 parasitic effect Effects 0.000 description 1
• 230000008775 paternal effect Effects 0.000 description 1
• 208000008016 pathologic nystagmus Diseases 0.000 description 1
• 230000007170 pathology Effects 0.000 description 1
• OYHFEIYRVJBRMG-UHFFFAOYSA-N pentyl(triphenyl)phosphanium Chemical compound C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(CCCCC)C1=CC=CC=C1 OYHFEIYRVJBRMG-UHFFFAOYSA-N 0.000 description 1
• 208000011906 peptic ulcer disease Diseases 0.000 description 1
• 230000002093 peripheral effect Effects 0.000 description 1
• 230000002085 persistent effect Effects 0.000 description 1
• 125000001792 phenanthrenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 description 1
• XYFCBTPGUUZFHI-UHFFFAOYSA-O phosphonium Chemical compound [PH4+] XYFCBTPGUUZFHI-UHFFFAOYSA-O 0.000 description 1
• 125000004437 phosphorous atom Chemical group 0.000 description 1
• 229910052698 phosphorus Inorganic materials 0.000 description 1
• 230000026731 phosphorylation Effects 0.000 description 1
• 238000006366 phosphorylation reaction Methods 0.000 description 1
• 108091008695 photoreceptors Proteins 0.000 description 1
• 235000019175 phylloquinone Nutrition 0.000 description 1
• 239000011772 phylloquinone Substances 0.000 description 1
• SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
• MBWXNTAXLNYFJB-NKFFZRIASA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCC[C@H](C)CCC[C@H](C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-NKFFZRIASA-N 0.000 description 1
• 230000000704 physical effect Effects 0.000 description 1
• 230000001766 physiological effect Effects 0.000 description 1
• 230000035790 physiological processes and functions Effects 0.000 description 1
• 229960001898 phytomenadione Drugs 0.000 description 1
• 125000004193 piperazinyl group Chemical group 0.000 description 1
• 125000005936 piperidyl group Chemical group 0.000 description 1
• 239000000902 placebo Substances 0.000 description 1
• 229940068196 placebo Drugs 0.000 description 1
• 229920000642 polymer Polymers 0.000 description 1
• 102000054765 polymorphisms of proteins Human genes 0.000 description 1
• 125000001185 polyprenyl group Polymers 0.000 description 1
• 239000011148 porous material Substances 0.000 description 1
• 239000013641 positive control Substances 0.000 description 1
• 230000001323 posttranslational effect Effects 0.000 description 1
• 229910001414 potassium ion Inorganic materials 0.000 description 1
• 230000002028 premature Effects 0.000 description 1
• 230000013823 prenylation Effects 0.000 description 1
• 230000003518 presynaptic effect Effects 0.000 description 1
• 230000000861 pro-apoptotic effect Effects 0.000 description 1
• 238000012545 processing Methods 0.000 description 1
• 208000026526 progressive weakness Diseases 0.000 description 1
• 230000002035 prolonged effect Effects 0.000 description 1
• 230000001915 proofreading effect Effects 0.000 description 1
• 230000009023 proprioceptive sensation Effects 0.000 description 1
• 230000012846 protein folding Effects 0.000 description 1
• 230000004844 protein turnover Effects 0.000 description 1
• 229950003776 protoporphyrin Drugs 0.000 description 1
• 208000020016 psychiatric disease Diseases 0.000 description 1
• 230000001179 pupillary effect Effects 0.000 description 1
• 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
• 210000002804 pyramidal tract Anatomy 0.000 description 1
• 125000003373 pyrazinyl group Chemical group 0.000 description 1
• 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
• 125000003226 pyrazolyl group Chemical group 0.000 description 1
• 125000002098 pyridazinyl group Chemical group 0.000 description 1
• 125000004076 pyridyl group Chemical group 0.000 description 1
• 125000000714 pyrimidinyl group Chemical group 0.000 description 1
• 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
• 125000001422 pyrrolinyl group Chemical group 0.000 description 1
• 125000000168 pyrrolyl group Chemical group 0.000 description 1
• 229940107700 pyruvic acid Drugs 0.000 description 1
• 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
• 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
• 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
• 230000007342 reactive astrogliosis Effects 0.000 description 1
• 230000008707 rearrangement Effects 0.000 description 1
• 230000000306 recurrent effect Effects 0.000 description 1
• 239000013074 reference sample Substances 0.000 description 1
• 238000011160 research Methods 0.000 description 1
• 201000004193 respiratory failure Diseases 0.000 description 1
• 230000004044 response Effects 0.000 description 1
• 210000001525 retina Anatomy 0.000 description 1
• 230000004258 retinal degeneration Effects 0.000 description 1
• 238000004007 reversed phase HPLC Methods 0.000 description 1
• PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
• 230000028710 ribosome assembly Effects 0.000 description 1
• 102200110006 rs121918052 Human genes 0.000 description 1
• 102200109875 rs121918054 Human genes 0.000 description 1
• 102200110007 rs145843073 Human genes 0.000 description 1
• 102220022922 rs386834147 Human genes 0.000 description 1
• 102220018591 rs397509392 Human genes 0.000 description 1
• 102200161560 rs587777004 Human genes 0.000 description 1
• 102200110013 rs61752783 Human genes 0.000 description 1
• 102220343951 rs767138032 Human genes 0.000 description 1
• 230000004434 saccadic eye movement Effects 0.000 description 1
• 230000037390 scarring Effects 0.000 description 1
• 208000037118 sensory ataxia Diseases 0.000 description 1
• 201000005572 sensory peripheral neuropathy Diseases 0.000 description 1
• 208000013223 septicemia Diseases 0.000 description 1
• 238000012163 sequencing technique Methods 0.000 description 1
• 230000009919 sequestration Effects 0.000 description 1
• 230000011664 signaling Effects 0.000 description 1
• 239000011734 sodium Substances 0.000 description 1
• 230000001148 spastic effect Effects 0.000 description 1
• 238000004611 spectroscopical analysis Methods 0.000 description 1
• 210000000278 spinal cord Anatomy 0.000 description 1
• 210000003594 spinal ganglia Anatomy 0.000 description 1
• 208000000995 spontaneous abortion Diseases 0.000 description 1
• 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
• 238000010186 staining Methods 0.000 description 1
• 208000001162 steatorrhea Diseases 0.000 description 1
• 239000003270 steroid hormone Substances 0.000 description 1
• 208000002254 stillbirth Diseases 0.000 description 1
• 231100000537 stillbirth Toxicity 0.000 description 1
• 238000003860 storage Methods 0.000 description 1
• 125000005017 substituted alkenyl group Chemical group 0.000 description 1
• 125000000547 substituted alkyl group Chemical group 0.000 description 1
• 125000004426 substituted alkynyl group Chemical group 0.000 description 1
• 238000006467 substitution reaction Methods 0.000 description 1
• 150000003457 sulfones Chemical class 0.000 description 1
• 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
• 150000003462 sulfoxides Chemical class 0.000 description 1
• 239000011593 sulfur Substances 0.000 description 1
• 230000009469 supplementation Effects 0.000 description 1
• 230000035900 sweating Effects 0.000 description 1
• 230000002195 synergetic effect Effects 0.000 description 1
• 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
• 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
• 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
• 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
• 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 1
• 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
• 125000003831 tetrazolyl group Chemical group 0.000 description 1
• 230000000542 thalamic effect Effects 0.000 description 1
• 210000001103 thalamus Anatomy 0.000 description 1
• 238000002560 therapeutic procedure Methods 0.000 description 1
• 125000001984 thiazolidinyl group Chemical group 0.000 description 1
• 125000000335 thiazolyl group Chemical group 0.000 description 1
• 125000001544 thienyl group Chemical group 0.000 description 1
• 125000004001 thioalkyl group Chemical group 0.000 description 1
• 150000003568 thioethers Chemical class 0.000 description 1
• 150000003573 thiols Chemical class 0.000 description 1
• 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
• FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
• 125000001425 triazolyl group Chemical group 0.000 description 1
• PVSCDXRWBXAXJW-UHFFFAOYSA-N tributyl(decyl)azanium Chemical compound CCCCCCCCCC[N+](CCCC)(CCCC)CCCC PVSCDXRWBXAXJW-UHFFFAOYSA-N 0.000 description 1
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
• GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 1
• RIOQSEWOXXDEQQ-UHFFFAOYSA-O triphenylphosphanium Chemical compound C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-O 0.000 description 1
• JFJZZMVDLULRGK-URLMMPGGSA-O tubocurarine Chemical compound C([C@H]1[N+](C)(C)CCC=2C=C(C(=C(OC3=CC=C(C=C3)C[C@H]3C=4C=C(C(=CC=4CCN3C)OC)O3)C=21)O)OC)C1=CC=C(O)C3=C1 JFJZZMVDLULRGK-URLMMPGGSA-O 0.000 description 1
• 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
• 210000003854 type 2 muscle cell Anatomy 0.000 description 1
• 150000003669 ubiquinones Chemical group 0.000 description 1
• JOYRKODLDBILNP-UHFFFAOYSA-N urethane group Chemical group NC(=O)OCC JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
• 210000004291 uterus Anatomy 0.000 description 1
• MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 1
• 229960000604 valproic acid Drugs 0.000 description 1
• 230000002792 vascular Effects 0.000 description 1
• 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
• 229920002554 vinyl polymer Polymers 0.000 description 1
• 230000008403 visual deficit Effects 0.000 description 1
• 230000004382 visual function Effects 0.000 description 1
• 235000019156 vitamin B Nutrition 0.000 description 1
• 239000011720 vitamin B Substances 0.000 description 1
• 235000011912 vitamin B7 Nutrition 0.000 description 1
• 239000011735 vitamin B7 Substances 0.000 description 1
• 230000008673 vomiting Effects 0.000 description 1
• 238000007482 whole exome sequencing Methods 0.000 description 1
• 102000018441 wolframin Human genes 0.000 description 1